KR101688542B1 - Functional Food Composition Comprising Red Ginseng Mixed Composition and Manufacturing Method Thereof - Google Patents
Functional Food Composition Comprising Red Ginseng Mixed Composition and Manufacturing Method Thereof Download PDFInfo
- Publication number
- KR101688542B1 KR101688542B1 KR1020160099334A KR20160099334A KR101688542B1 KR 101688542 B1 KR101688542 B1 KR 101688542B1 KR 1020160099334 A KR1020160099334 A KR 1020160099334A KR 20160099334 A KR20160099334 A KR 20160099334A KR 101688542 B1 KR101688542 B1 KR 101688542B1
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- fermented
- composition
- mixed
- fermentation
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 166
- 239000000203 mixture Substances 0.000 title claims abstract description 134
- 235000013376 functional food Nutrition 0.000 title abstract description 28
- 238000004519 manufacturing process Methods 0.000 title description 11
- 238000000855 fermentation Methods 0.000 claims abstract description 62
- 230000004151 fermentation Effects 0.000 claims abstract description 62
- 239000011812 mixed powder Substances 0.000 claims abstract description 49
- 239000000843 powder Substances 0.000 claims abstract description 41
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 35
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 33
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 32
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 19
- 244000068988 Glycine max Species 0.000 claims abstract description 19
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 19
- 235000008397 ginger Nutrition 0.000 claims abstract description 19
- 241000255789 Bombyx mori Species 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000012141 concentrate Substances 0.000 claims abstract description 14
- 235000004952 turnera diffusa Nutrition 0.000 claims abstract description 11
- 230000032683 aging Effects 0.000 claims abstract description 10
- 244000005700 microbiome Species 0.000 claims abstract description 10
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000005507 spraying Methods 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 27
- 241000408747 Lepomis gibbosus Species 0.000 claims description 11
- 235000020236 pumpkin seed Nutrition 0.000 claims description 10
- 241000190633 Cordyceps Species 0.000 claims description 8
- 239000002285 corn oil Substances 0.000 claims description 8
- 235000005687 corn oil Nutrition 0.000 claims description 8
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 4
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 4
- 244000082204 Phyllostachys viridis Species 0.000 claims description 4
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 4
- 239000011425 bamboo Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 2
- 240000000289 Turnera ulmifolia Species 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 240000000143 Turnera diffusa Species 0.000 abstract description 11
- 241000209020 Cornus Species 0.000 abstract description 5
- 241000282461 Canis lupus Species 0.000 abstract description 4
- 244000197580 Poria cocos Species 0.000 abstract description 4
- 235000008599 Poria cocos Nutrition 0.000 abstract description 4
- 235000009854 Cucurbita moschata Nutrition 0.000 abstract description 3
- 235000009206 Turnera diffusa Nutrition 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 235000000832 Ayote Nutrition 0.000 abstract 2
- 240000001980 Cucurbita pepo Species 0.000 abstract 2
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 abstract 2
- 235000015136 pumpkin Nutrition 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 119
- 230000000694 effects Effects 0.000 description 110
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 77
- 235000005911 diet Nutrition 0.000 description 47
- 241000700159 Rattus Species 0.000 description 38
- 229960003180 glutathione Drugs 0.000 description 37
- 108010024636 Glutathione Proteins 0.000 description 36
- 201000001881 impotence Diseases 0.000 description 35
- 208000010228 Erectile Dysfunction Diseases 0.000 description 33
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 31
- 230000037213 diet Effects 0.000 description 31
- 230000036299 sexual function Effects 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 230000006872 improvement Effects 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 22
- 210000001550 testis Anatomy 0.000 description 21
- -1 hydroxyl radicals Chemical class 0.000 description 20
- 210000005228 liver tissue Anatomy 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 18
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 18
- 230000000378 dietary effect Effects 0.000 description 16
- 230000002440 hepatic effect Effects 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 240000004371 Panax ginseng Species 0.000 description 15
- 235000008434 ginseng Nutrition 0.000 description 15
- 235000018823 dietary intake Nutrition 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 235000013305 food Nutrition 0.000 description 13
- 230000003859 lipid peroxidation Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 12
- 108010082126 Alanine transaminase Proteins 0.000 description 12
- 102000005720 Glutathione transferase Human genes 0.000 description 12
- 108010070675 Glutathione transferase Proteins 0.000 description 12
- 241000234314 Zingiber Species 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 102000006587 Glutathione peroxidase Human genes 0.000 description 11
- 108700016172 Glutathione peroxidases Proteins 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000002381 testicular Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 235000008504 concentrate Nutrition 0.000 description 10
- 238000001784 detoxification Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000004792 oxidative damage Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- 229960002666 1-octacosanol Drugs 0.000 description 9
- 102000016938 Catalase Human genes 0.000 description 9
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 9
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000000451 tissue damage Effects 0.000 description 9
- 231100000827 tissue damage Toxicity 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- 241000194108 Bacillus licheniformis Species 0.000 description 8
- 108010053835 Catalase Proteins 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 210000005226 corpus cavernosum Anatomy 0.000 description 8
- 235000020188 drinking water Nutrition 0.000 description 8
- 239000003651 drinking water Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 150000003568 thioethers Chemical class 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000011345 viscous material Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 241000168720 Panax japonicus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000020710 ginseng extract Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 238000006701 autoxidation reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 3
- 230000021595 spermatogenesis Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229940094720 viagra Drugs 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 241000554155 Andes Species 0.000 description 2
- 241000194103 Bacillus pumilus Species 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001264174 Cordyceps militaris Species 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241000801118 Lepidium Species 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000002790 anti-mutagenic effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000003028 enzyme activity measurement method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000010200 folin Substances 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000281 testicular toxicity Toxicity 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- VHOCUJPBKOZGJD-UHFFFAOYSA-N triacontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VHOCUJPBKOZGJD-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 2
- 229930001895 zingiberene Natural products 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- GYZVCMCORBRKLC-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O.OC(=O)C1=CC=CC=C1[N+]([O-])=O GYZVCMCORBRKLC-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000511582 Actinomyces meyeri Species 0.000 description 1
- 208000021769 Acute sensory ataxic neuropathy Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000122821 Aspergillus kawachii Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000266830 Bacillus sonorensis Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000255783 Bombycidae Species 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 description 1
- 241000414067 Inonotus obliquus Species 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- XACHQDDXHDTRLX-GMPBGBGESA-N Physalien Natural products O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)=C(C)C1)CCCCCCCCCCCCCCC XACHQDDXHDTRLX-GMPBGBGESA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- SZFSLWMLMWUDEG-UHFFFAOYSA-N S(=O)(=O)(O)C(=O)C1=CC(OC)=C(OP(=O)=O)C=C1 Chemical compound S(=O)(=O)(O)C(=O)C1=CC(OC)=C(OP(=O)=O)C=C1 SZFSLWMLMWUDEG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 206010043298 Testicular atrophy Diseases 0.000 description 1
- 206010051872 Testicular injury Diseases 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 201000010788 atrophy of testis Diseases 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QQGLQYQXUKHWPX-SUYBVFMFSA-N benzyl glucosinolate Natural products S(=O)(=O)(O/N=C(/S[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O1)\Cc1ccccc1)O QQGLQYQXUKHWPX-SUYBVFMFSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- OIDPCXKPHYRNKH-UHFFFAOYSA-J chrome alum Chemical compound [K]OS(=O)(=O)O[Cr]1OS(=O)(=O)O1 OIDPCXKPHYRNKH-UHFFFAOYSA-J 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 108010083364 chungkookjang Proteins 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- 229910000009 copper(II) carbonate Inorganic materials 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 239000011646 cupric carbonate Substances 0.000 description 1
- 235000019854 cupric carbonate Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- QQGLQYQXUKHWPX-RFEZBLSLSA-N glucotropeolin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S\C(=N/OS(O)(=O)=O)CC1=CC=CC=C1 QQGLQYQXUKHWPX-RFEZBLSLSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 description 1
- 235000002279 indole-3-carbinol Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- 230000023508 male gonad development Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011656 manganese carbonate Substances 0.000 description 1
- 235000006748 manganese carbonate Nutrition 0.000 description 1
- 229940093474 manganese carbonate Drugs 0.000 description 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229930184989 physalin Natural products 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229960001109 policosanol Drugs 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 231100001044 testicular atrophy Toxicity 0.000 description 1
- 231100000398 testicular damage Toxicity 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- XACHQDDXHDTRLX-HZXCUAKRSA-N zeaxanthin dipalmitate Chemical compound CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC1(C)C XACHQDDXHDTRLX-HZXCUAKRSA-N 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 홍삼 분말 및 발효 혼합 분말로 이루어진 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물 및 이의 제조방법에 관한 것으로, 더욱 상세하게는 홍삼 분말 및 발효 혼합 분말의 홍삼 발효 혼합 조성물을 포함하여 간 해독, 활성산소 소거, 알코올성 발기부전, 성기능 개선의 효과를 나타내는 기능성 식품 조성물 및 이의 제조방법에 관한 것이다.The present invention relates to a functional food composition comprising a red ginseng fermented mixed composition comprising red ginseng powder and fermented mixed powder, and more particularly, to a functional food composition containing red ginseng fermented mixed composition of red ginseng powder and fermented mixed powder, Active oxygen scavenging, alcoholic erectile dysfunction, sexual function improvement, and a method for producing the functional food composition.
최근 의학의 발전에 따른 인간의 평균수명 증가와 더불어 건강이 보장된 삶의 질에 향상에 대한 요구가 그 어느 때보다 높아지고 있으며, 개인의 건강지수를 향상시키기 위한 방법의 일환으로 자연 건강기능식품에 대한 관심이 증가하고 있다. In recent years, with the increase in the average life span of human beings due to the advancement of medicine, the demand for improvement in the quality of life guaranteed by health has been higher than ever. As a method for improving the individual's health index, Interest is growing.
이러한 추세에 힘입어 기능성을 가진 생약이나 허브식물 등 동식물을 포함하는 천연물을 이용한 건강기능성 식품의 개발이 전 세계적으로 진행되고 있다.Due to this tendency, the development of health functional foods using natural products including plant and animal products such as herbal medicines and herb plants with functional properties is being developed all over the world.
일반적으로 천연물들은 합성품에 비해 생체 내 독성과 부작용이 낮을 뿐만 아니라 생활습관병의 예방, 항산화, 항노화, 항암효과 등 다양한 생리활성을 나타냄으로서 질병을 예방하는 것으로 알려져 있다. In general, natural products are less toxic and adverse in vivo than synthetic products, and they are known to prevent diseases by exhibiting various physiological activities such as prevention of lifestyle diseases, antioxidation, anti-aging and anti-cancer effect.
한편, 성기능 장애는 심한 경우 자신감 상실, 무력감, 부정적인 대인관계 등과 함께 사회문제로까지 부각될 수 있다. 특히 남성의 경우 발기부전(ED: erectile dysfunction)은 국내인 뿐만 아니라 전 세계 남성의 가장 보편적이며 공통적인 성기능 장애로 환자의 수나 치료비용 및 이에 의한 정신적 충격 등을 고려해 본다면 중요한 사회적 공중보건문제로 대두되고 있다(NIH Consensus Conference. NIH Consensus Development Panel on impotence. JAMA. 270: 83-90, 1993). On the other hand, sexual dysfunction can be a serious social problem as well as loss of self-confidence, powerlessness, and negative interpersonal relationships. In particular, erectile dysfunction (ED) is the most common and common sexual dysfunction among males in the world, not only in Korea but also in male patients. Considering the number of patients, the cost of treatment and the psychological shock caused by them, (NIH Consensus Conference, NIH Consensus Development Panel on impotence, JAMA, 270: 83-90, 1993).
최근 비아그라(viagra)를 포함한 기타 경구용 ED 치료약의 개발되어 이용되고 있으나 ED 문제가 완전히 해소시키지는 못하고 있는 실정이다. 즉 이와 같은 의약품은 발기부전증세의 일시적 완화제이며 ED를 근본적으로 치료하지 못할 뿐만 아니라 경비 문제와 더불어 장기 복용으로 인한 부작용 또한 심각한 것으로 보고되고 있다. 그러므로 비아그라 등과 같은 합성 ED 치료제보다 안전하고, 기능성이 뛰어난 천연물질을 이용한 성기능 증진제를 개발하는 것은 국민의 보건과 복지의 관점에서 볼 때, 건강유지와 ED 개선에 도움이 될 뿐만 아니라, 의료비 절감과 부작용 감소 등을 통하여 치료 수혜자의 범위를 확대할 수 있을 것으로 기대된다.Recently, other oral ED drugs including Viagra have been developed and used, but ED problems are not completely solved. In other words, these medicines are temporary relieving agents of erectile dysfunction, and they are not able to cure the ED fundamentally, and it is reported that the side effects due to long-term use as well as the cost problems are serious. Therefore, the development of a sexual enhancement agent using natural substances that are safer and more functional than synthetic ED agents such as Viagra is not only helpful in improving health and ED, but also in reducing medical costs It is expected that the scope of the beneficiary will be expanded through the reduction of side effects.
최근 약용식물과 허브 류 등의 천연물질에 의한 성기능 개선효과 및 관련 파이토케미칼(phytochemicals)의 생리기능조절에 의한 ED 효능 기전이 보고되었으며(MacKay D., Nutrients and botanicals for erectile dysfunction: Examining the evidence. Altern. Med. Rev. 9: 4-16, 2004; Adimoelja A., Phytochemicals and the breakthrough of traditional herbs in the management of sexual dysfunctions. Int. J. Androl. 23: 82-84, 2000), 천연물 중에 특히 마카(Maca)로 명명되고 있는 십자화과의 Lepidium meyenii는 스태미너와 성기능 증진 효능이 있어 안데스의 인삼(Ginseng of the Andes)으로 알려져 있다(Rea J. Andean roots. In: Neglected crops: 1492 from a different perspective. Hernando J. E. and Seon J., eds. p. 165-179, Plant production and protection series No 26, FAO, Rome, Italy, 1994). Recently, it has been reported that the ED effect is mediated through the regulation of the physiological functions of phytochemicals and sexual function improvement by natural substances such as medicinal plants and herbs (MacKay D., Nutrients and botanicals for erectile dysfunction: Examining the evidence. Int. J. Androl. 23: 82-84, 2000), among the natural products, in particular, Of the crucifix named Maca Lepidium Meyenii is known as Ginseng of the Andes because it has a stamina and sexual enhancement efficacy (Rea J. Andean roots.In: Neglected crops: 1492 from a different perspective.Hernando JE and Seon J., eds. 165-179, Plant production and protection series No. 26, FAO, Rome, Italy, 1994).
마카는 페루 안데스지역의 전통 약용식물로서 고도 4,000~4,500m에서 자생하며, 특히 뿌리부분에 열량영양소와 칼슘, 철분 등의 무기질이 풍부하여 인디안 원주민들이 피로회복과 빈혈, 결핵, 불임 등에 이용해 왔다. 마카에서 약리적 활성을 가진 macaenes과 macamides가 분리되었으며(Ganzera M., Zhao J., Muhammad H, Khan IA. Chemical profiling and standardization of Lepidium meyenii(Maca) by reversed phase high performance liquid chromatography. Chem. Pharm. Bull. 50: 988-991, 2002; Piacente S., Carbone V., Plaza A., Zampelli A., Pizza C., Investigation of the tuber constituents of maca(Lepidium meyenii Walp.). J. Agri. Food. Chem. 50: 5621-5625, 2002) 마카의 benzyl glucosinolate는 장내 미생물에 의하여 chemoprotective activity를 가진 isothiocyanate, indole-3-carbinol로 분해되어 전립선암과 전립선 비대의 예방효과가 있다고 보고된 바 있다(Gonzales G. F., Miranda S., Nieto J., Fernandez G., Yucra S., Rubio J., Yi P., Gasco M., Red maca reduced prostate size in rats. Reprod. Biol. Endocrinol. 3: 5-32, 2005). Maca is a traditional medicinal plant in the Andes region of Peru. It grows at an altitude of 4,000 ~ 4,500m, and its nutrients, calcium, iron and other minerals are abundant in its roots, and indigenous peoples have been used for fatigue, anemia, tuberculosis and infertility. Macaenes and macamides with pharmacological activity were isolated from maca (Ganzera M., Zhao J., Muhammad H, Khan IA. Chemical profiling and standardization of Lepidium meyenii (Maca) by reversed phase high performance liquid chromatography. Chem. Pharm. Bull. 50: 988-991,2002; Piacente S., Carbone V., Plaza A., Zampelli A., Pizza C., Investigation of the tuber constituents of maca ( Lepidium meyenii Walp.). J. Agri. Food. Chem. 50: 5621-5625, 2002) The benzyl glucosinolate of maca has been reported to be degraded into isothiocyanate, indole-3-carbinol, which has chemoprotective activity by intestinal microorganisms, to prevent prostate cancer and prostate enlargement (Gonzales GF, Miranda S., Nieto J., Fernandez G., Yucra S., Rubio J., Yi P., Gasco M., Red maca reduced prostate size in rats.Reprod. Biol. Endocrinol.3: 5-32, 2005).
마카를 흰쥐에 투여하였을 때, 수컷 흰쥐에서는 정자형성 촉진(Gonzales G. F., Ruiz A., Gonzales C., Villegas L., Cordova A.. Effect of Lepidium metenii(maca) roos on spermatogenesis of male rats. Asian J. Androl. 3: 231-233, 2001; Gonzales C., Rubio J., Gasco M., Nieto J., Yucra S., Gonzales G. F., Effect of short-term and long-term treatments with three ecotypes of Lepidium meyenii(Maca) on permatogenesis in rats. J. Ethnopharmacol. In Press, 2005), 성기능 강화(Cicero A. F. G., Bandieri E., Arletti R., Lepidium meyenii Walp improves sexual behaviour in male rats idependently from its action on spontaneous locomotor activity. J. Ethnopharmacol. 75: 225-229, 2001), malathion에 의해 손상된 정자형성과정의 활성화가 나타나며(Bustos-Obregon E., Yucra S., Gonzales G. F., Lepidium meyenii(Maca) reduces spermatogenic damage induced by a single dose of malathion in mice. Asian J. Androl. 7: 71-76, 2005), 암컷 쥐에서는 수태능력이 향상된다(Ruiz-Luna A. C., Salazar S., Aspajo N. J., Rubio J., Gasco M., Gonzales G. F., Lepidium meyenii(Maca) increases litter size in normal adult female mice. Reprod. Biol. Endocrinol. 3: 3-16, 2005). 또, 성인 남성에게 투여 시 성생활 개선효과 더불어 정자 형성 촉진 및 정자의 운동성 증가 등이 보고되고 있어 성 기능 개선 관련 천연물로 주목받고 있다(Gonzales G. F., Cordova A., Vega K., Chung A., Villena A., Gonez C., Castillo S., Effect of Lepidium meyenii(Maca) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Androl. 34: 367-372, 2002; Gonzales G. F., Cordova A., Gonzales C., Chung A., Vega K., Villena A., Lepidium meyenii(Maca) improved semen parameters in adult men. Asian J. Androl. 3: 301-303, 2003).When the maca were administered to rats, the spermatogenesis was promoted in male rats (Gonzales GF, Ruiz A., Gonzales C., Villegas L., Cordova A .. Effects of Lepidium metenii (maca) roos on spermatogenesis of male rats. Asian J. Androl. 3: 231-233,2001; Gonzales C., Rubio J., Gasco M., Nieto J., Yucra S., Gonzales GF, Effect of short-term and long-term treatments with three ecotypes of Lepidium meyenii (Maca) on permatogenesis in rats. J. Ethnopharmacol. In Press, 2005), sexual enhancement (Cicero AFG, Bandieri E., Arletti R., Lepidium Walpel improves sexual behavior in male rats idependently from its action on spontaneous locomotor activity. J. Ethnopharmacol. (Bustos-Obregon E., Yucra S., Gonzales GF, and Lepidium meyenii (Maca)) induced spermatogenic damage by a single dose of malathion (Riziz-Luna AC, Salazar S., Aspajo NJ, Rubio J., Gasco M., Gonzales GF, Lepidium meyenii (Maca) increases litter size in normal adult female mice. Reprod. Biol. Endocrinol. 3: 3-16, 2005). In addition, it has been reported that sexual function enhancement, spermatogenesis and sperm motility are increased in adult men, and it is attracting attention as a natural product related to sexual function improvement (Gonzales GF, Cordova A., Vega K., Chung A., Villena A., Gonez C., Castillo S., Effect of Lepidium meyenii (Maca) on testosterone levels in adult healthy men. Androl. 34: 367-372, 2002; Gonzales GF, Cordova A., Gonzales C., Chung A., Vega K., Villena A., Lepidium meyenii (Maca) improved semen parameters in adult men. Asian J. Androl. 3: 301-303, 2003).
한편, 칼로리 증강 또는 치료효과가 아니라 생리기능 조절효과를 가진 생약 중, 국내외에 널리 알려져 있는 인삼(Panax ginseng)은 한국의 전통건강식품으로서 체력 증강과 강정 및 피로회복에 유용한 기능성 식품이나 의약품에 이용되고 있다(Bucci L. R., Selected herbals and human exercise performance. Am J Clinc Nutr. 72: 624S-636, 2000). 인삼은 중추신경계 자극, 조직 단백질의 합성, 면역력 증강, 항산화력 강화 등의 다양한 약리작용을 가지고 있으며(Bahrke M. S., Morgan WP. Evaluation of the ergogenic properties of ginseng. Sports Med. 18: 229-248, 1994; Hobbs C., The ginsengs. A user's guide. Santa Cruz, CA, Botanica Press, 1996; Zhang D., Yasuda T., Yu Y., Zheng P., Kawabata T., Ma Y., Okada S., Ginseng extract scavenges hydroxyl radical and protects unsaturated fatty acids from decomposition caused by iron-mediated lipid peroxidation. Free Radic Biol. Med. 20: 145-150, 1996), 이러한 인삼의 효능은 주성분인 사포닌(ginsenosides)에 의한 생체효소의 비 특이적 자극효과(nonspecific stimulatory effects)에 의한 것으로 알려졌다(Chung N. J., Some physiological and biochemical aspects of saponin fraction of Panax Ginseng C.A. Meyer. Kor. J. Ginseng Sci. 14: 143-156, 1990; Joo C. N., Several physiological functions and metabolism of ginsenosides in the animal body. Kor. J. Ginseng Sci. 17; 250-286, 1993). 또한 인삼은 성기능 강화 또는 성기능 회복효과가 있는 것으로 보고되고 있으며(Murphy L. L., Lee T. J., Ginseng, sex behavior, and nitric oxide. Annals NY Acad Sci. 962: 372-377, 2002), On the other hand, Panax ginseng, which is widely known at home and abroad among the herbal medicines that have not the effect of caloric enhancement or treatment, has a physiological function controlling effect. It is a traditional Korean health food. It is used for functional foods and medicines useful for strengthening physical strength and restoring fatigue and fatigue (Bucci LR, Selected herbals and human exercise performance, Am J Clinc Nutr. 72: 624S-636, 2000). Ginseng has various pharmacological actions such as stimulation of central nervous system, synthesis of tissue proteins, enhancement of immunity, strengthening of antioxidant power (Bahrke MS, Morgan WP. Evaluation of the ergogenic properties of ginseng. Sports Med. 18: 229-248, 1994 Yasuda T., Yu Y., Zheng P., Kawabata T., Ma Y., Okada S., < RTI ID = 0.0 > Ginseng extract scavenges hydroxyl radicals and protects unsaturated fatty acids from decomposition caused by iron-mediated lipid peroxidation. Free Radic Biol. Med. 20: 145-150, 1996) (Chung NJ, Some physiological and biochemical aspects of saponin fraction of Panax Ginseng CA Meyer. Kor J. Ginseng Sci. 14: 143-156, 1990; Joo CN , Several physiological functions and metabolism of ginsenosides in t he animal body. Kor J. Ginseng Sci. 17: 250-286, 1993). In addition, ginseng has been reported to have sexual or sexual restorative effects (Murphy L. L., Lee T. J., Ginseng, sex behavior, and nitric oxide. Annals NY Acad Sci. 962: 372-377,
특히 한국산 인삼을 가공한 홍삼은 조사포닌과 주요 ginsenosides의 함량이 높으며(Lee J. W., Lee S. K., Do J. H., Comparison of the content of saponin and mineral component in Korean red ginseng and other red ginseng. J. Ginseng Res. 26: 196-201, 2002), 발기부전환자의 ED 개선에 상당한 효과가 있는 것으로 보고되고 있다(Hong B., Ji Y. H., Hong J. H., Nam K. Y., Ahn T. Y., A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. J. Urol. 168: 2070-2073, 2002). In particular, red ginseng processed from Korean ginseng has a high content of crude saponin and major ginsenosides (Lee JW, Lee SK, Do JH, Comparison of the content of saponin and mineral component in Korean red ginseng and other red ginseng, J. Ginseng Res. 26, 196-201, 2002), it has been reported that ED has a significant effect on the improvement of ED in patients with erectile dysfunction (Hong B., Ji YH, Hong JH, Nam KY, Ahn TY, A double-blind crossover study, evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report, J. Urol., 168: 2070-2073, 2002).
최근 연구에서 홍삼은 성기능 장애환자의 정자 수 증가와 성기능 강화(Salvati G., Genovesi G., Marcellini L., Paolini P., De Nuccio I., Pepe M., Re M., Effects of Panax Ginseng C.A. Meyer saponins on male fertility. Panminerva Med. 38: 249-254, 1996), 난소기능 회복(Yu W. J., Lee B. J., Nam S. Y., Yang D. C., Yun Y. W., Modulating effects of korean ginseng saponins on ovarian function in immature rats. Bio. Pharm. Bull. 26: 1574-1580, 2003), 수태한 흰쥐의 조직세포 산화방지(Song Y. B., Kwak Y. S., Park K. H., Chang S. K., Effect of total saponin from red ginseng on activities of antioxidant enzymes in pregnant rats. J. Ginseng Res. 26: 139-144, 2002) 및 독성노출 흰쥐의 정자 기능성 회복(Hwang S. Y., Kim W. J., Wee J. J., Choi J. S., Kim S. K., Panax ginseng improves survival and sperm quality in guinea pigs exposed to 2,3,7,8-tetrachlorodi benzo-p-dioxin. BJU Int. 94: 663-668, 2004) 등에 영향을 미치는 것으로 확인되었다.In a recent study, red ginseng increased the number of sperm and increased sexual function in patients with sexual dysfunction (Salvati G., Genovesi G., Marcellini L., Paolini P., De Nuccio I., Pepe M., Re M., Effects of Panax Ginsengca (Yang WJ, Lee BJ, Nam SY, Yang DC, Yun YW, Modulating effects of Korean ginseng saponins on ovarian function in immature rats. Bio-Pharm Bull. 26: 1574-1580, 2003), Prevention of Tissue Cell Oxidation in Pregnant Rats (Song YB, Kwak YS, Park KH, Chang SK, Rats, J. Ginseng Res. 26: 139-144, 2002) and sperm function recovery in toxic exposed rats (Hwang SY, Kim WJ, Wee JJ, Choi JS, Kim SK, Panax ginseng improves survival and sperm quality in guinea pigs exposed to 2,3,7,8-tetrachlorodi benzo-p-dioxin. BJU Int. 94: 663-668, 2004) The.
또한, 대한민국 등록특허공보 10-0538717호에서는 홍삼 농축물과 구기자, 복분자, 오미자, 토사자, 사상자를 포함하는 홍삼 복합물을 통해 성기능 개선의 효과를 얻고 있으며, 대한민국 등록특허공보 10-1385657호에서는 홍삼 추출물, 마 추출물, 산수유 추출물, 구기자 추출물, 울금 추출물 및 벌꿀을 포함하는 조성물을 통해 남성 발기부전 예방 또는 치료의 효과를 얻고 있고, 대한민국 등록특허공보 10-0850503호에서는 산수유, 오미자, 가시오가피, 복분자, 홍삼, 마늘, 육계, 토사자, 두충, 건지황으로 구성된 복합 생약제로부터 얻은 생약 추출물을 통해 성기능 개선의 효과를 얻고 있다.In Korean Patent Registration No. 10-0538717, red ginseng concentrate and ginseng extract, bombyx mugwort, omija, tosaja, and casualty ginseng have obtained the effect of sexual function improvement. In Korean Patent Registration No. 10-1385657, red ginseng extract In the Korean Patent Registration No. 10-0850503, there is disclosed a composition for preventing or treating erectile dysfunction of male erectile dysfunction, wherein the composition comprises mung bean oil, omija, koshiogapi, bokbunja, ginseng extract, , Garlic, broiler, tosaja, japonica, and ginseng extract.
다미아나(Damiana, Turnera diffusa, Willd)는 남미와 미국 중서부에서 자생하는 식물로 남성과 여성들의 성 기능 강화, 오르가즘 증가 등의 효과를 얻을 수 있으며, 한방에서도 널리 사용되고 있는 입증된 허브이다. 노란 꽃을 피우는 관목으로 경작 또는 야생에서 서식하며, 잎은 여름에 개화할 때 수확하여 사용된다. Damiana, Turnera diffusa , Willd) is a plant native to South America and the Midwest, which can enhance the sexual function of males and females, increase orgasm, and is a proven herb widely used in oriental medicine. It is a yellow-blooming shrub that grows in the wild or cultivated, and leaves are harvested when blooming in the summer.
라틴아메리카 문명에서 수천 년 동안 성 강장제로 사용되어 왔으며, 선향(線香)을 만들어 향불을 피워 신경안정제로 사용되었다. 근래에 들어 신규 구조를 갖는 플라본 글리코시드 물질 및 플라보노이드의 유효물질이 동정 되었으며, 성 기능 강화 이외에 어지럼증 개선, 항불안(anti-anxiety), 항우울증(anti-depress) 등의 기능 등이 보고된 바 있으며, 천식, 감기 증상의 완화, 월경에 의한 두통 완화, 변비를 완화시키는데 사용되는 순환 이완제로도 사용되고 있다.It has been used as a tonic for thousands of years in Latin American civilization, and has been used as a nervous stabilizer by making incense sticks (incense sticks). In recent years, effective substances of flavon glycoside materials and flavonoids having a novel structure have been identified. In addition to enhancing sexual function, functions such as improvement of dizziness, anti-anxiety, and anti-depression have been reported It is also used as a circulatory reliever for relieving asthma, relieving cold symptoms, relieving headache due to menstruation, and relieving constipation.
호박씨에는 비타민 B, C, E와 효소인 urease가 있고, 기름이 약 40~50%로 주성분으로는 리놀산, 올레산, 팔미트산, 스테아르산이 알려져 있다(Procida G., Stancher B., Cateni F., Zacchigna M., Chemical composition and functional characterization of commercial pumpkin seed oil. J. Sci. Food Agric. 93: 1035-1041, 2012). 대부분은 불포화지방산인 리놀산과 올레산으로 이루어져 있으며, 리놀산은 항염증 작용이 잘 알려져 있고, 올레산은 상처 치료, 면역 및 염증 질환과 암에 효과가 있는 것으로 알려지고 있다.Pumpkin seeds contain vitamins B, C and E and urease, which is an enzyme, and about 40 ~ 50% of oil. Linoleic acid, oleic acid, palmitic acid and stearic acid are known as main components (Procida G., Stancher B., Cateni F. , Zacchigna M., Chemical composition and functional characterization of commercial pumpkin seed oil, J. Sci. Food Agric. 93: 1035-1041, 2012). Most of them are composed of unsaturated fatty acids linoleic acid and oleic acid. Linoleic acid is well known for its antiinflammatory action, and oleic acid is known to be effective in wound healing, immunity and inflammatory diseases and cancer.
대두는(Soybean, Glycine max L) 대두단백, 펩티드, 올리고당, 인지질, 이소플라본, 사포닌, 무기질과 비타민 등이 함유되어 있으며, 사포닌, 플라보노이드 등 생리활성성분이 다량 함유되어 있다. 대두단백은 혈중 콜레스테롤, 혈중 지단백질(LDL) 농도를 감소시킴으로써 동맥경화증과 심장병 예방효과가 있고, 대두 올리고당은 장내 유용균의 번식을 촉진시키고, 대두 식이섬유소는 콜레스테롤 배설촉진, 장기능 개선효과, 식 후 혈당 상승과 인슐린 분비억제 등 효과가 있는 것으로 알려져 있다.Soybean (Soybean, Glycine max L) soy protein, and a peptide, oligosaccharide, phospholipid, isoflavones, saponins, vitamins and minerals and is contained, the physiologically active ingredient of saponin, a flavonoid, such as the large amount. Soybean protein reduces blood cholesterol and blood lipoprotein (LDL) concentration, thereby preventing atherosclerosis and heart disease. Soybean oligosaccharide promotes propagation of enterobacteria in the intestines. Soybean fiber promotes cholesterol excretion, It is known that there are effects such as increase of blood sugar and suppression of insulin secretion.
대두 사포닌은 비만억제, 혈중 콜레스테롤의 감소, 항암, 인간 면역 결핍 바이러스(human immunodeficiency virus, HIV) 증식억제, 노화방지 등의 작용을 지니며, 그 외 대두성분은 피부암, 방광암, 폐암, 결장암, 췌장암, 식도암, 전립선압, 간압, 위암 등에도 유효함이 연구를 통해 밝혀진 바 있다.Soybean saponin has the functions of inhibition of obesity, reduction of blood cholesterol, anticancer, inhibition of human immunodeficiency virus (HIV) proliferation, anti-aging, etc. The other soybean components are skin cancer, bladder cancer, lung cancer, colon cancer, pancreatic cancer , Esophageal cancer, prostate pressure, liver pressure, and gastric cancer.
생강(Zingiber officinale Roscoe)은 열대 아시아가 원산지인 생강과에 속하는 다년생 작물로 한방에서는 위를 튼튼하게 하는 건위약(建胃藥)으로 사용되어 왔고 소화불량, 구토, 진통에 효과가 있다고 알려져 있다. 생강에는 zingiberene, γ-cardinen 등의 휘발성 향기성분과 zingiberol, zingiberene 등의 정유성분이 함유되어 있다. 특히 생강 특유의 맛을 내는 oleoresin은 여러 동족체의 혼합물로 존재하며, 이중 6-gingerol 및 6-shogaol은 항균 작용, 함염작용, 혈청 콜레스테롤 저하 효과, 항산화 작용이 있어, 건강기능식품 소재로 주목받고 있다(Sheo H. J., The antibacterial action of garlic, onion, ginger and red pepper juice. J. Kor. Soc. Food Sci. Nutr. 28: 94-99, 1999; Lee E. J., Yang S. A., Choi H. D., Im H. G., Whang K., Lee I. S., Comparison of gingerols in various fractions and the antioxidant effects of supercritical fluid extracts from ginger. Kor. J. Food Sci. Technol. 43: 469-474, 2011).Ginger (Zingiber officinale Roscoe) is a perennial crop belonging to the ginger family originating in tropical Asia. It has been used as a stomach medicine to strengthen the stomach in a herb and is said to be effective in digestion, vomiting and pain. Ginger contains volatile fragrance components such as zingiberene and γ-cardinen, and essential oils such as zingiberol and zingiberene. Especially, oleoresin, which is a unique taste of ginger, exists as a mixture of several homologs. Among them, 6-gingerol and 6-shogaol are attracting attention as a health functional food material because they have antibacterial action, salt action, serum cholesterol lowering effect and antioxidant action (Sheo HJ, The antibacterial action of garlic, onion, ginger and red pepper juice, J. Kor. Soc. Food Sci. Nutr. 28: 94-99, 1999; K., Lee IS, Comparison of gingerols in various fractions and the antioxidant effects of supercritical fluid extracts from ginger, Kor J. Food Sci. Technol., 43: 469-474, 2011).
동충하초(冬蟲夏草)는 겨울철에는 여러 종의 곤충에 기생하였다가 여름이 되어 온도와 습도가 높아지면 곤충을 기주로 하여 자실체를 발생하거나 충체상에 포자를 형성하는 버섯의 한 종류이다. 중국의 고서들에 의하면 동충하초는 암질환, 간질환, 폐질환, 뇌질환, 순환기 질환, 심장병, 당뇨병 등에 탁원한 효과를 나타낼 뿐만 아니라, 현대실용 중약전에는 폐결핵, 노인쇠약성 만성결핵 빈혈, 허약체질 등을 치료한다고 나타나 있다.Cordyceps is a kind of mushroom which grows on insects as a host and forms spores on the larvae when the temperature and humidity become high in the summer when it becomes parasitic to various kinds of insects in winter. According to Chinese ancient books, Cordyceps is not only effective in cancer, liver disease, lung disease, brain disease, cardiovascular disease, heart disease, diabetes, etc., but it also has pulmonary tuberculosis, elderly debilitating chronic tuberculosis anemia, And the like.
최근에는 항암효과 및 마약 중독의 해독제로서도 효과가 있는 것으로 보고되고 있으며, 면역증강과 항균작용, 항당뇨 효과, 고지혈증 개선작용 및 혈소판 응집억제 작용이 보고되고 있다(Lee H. H., Cho H. S., The effect of Cordyceps militaris on adaptive immune responses in DBA2 mice inmmunized with influenza vaccine. Uakhak Hoeji. 59: 1-5, 2015).Recently, it has been reported to be effective as an anticancer and antidote to drug poisoning. Immune enhancement, antibiotic effect, antidiabetic effect, hyperlipidemia improving action and platelet aggregation inhibiting action have been reported (Lee HH, Cho HS, The effect of Cordyceps militaris on adaptive immune responses in DBA2 mice with immunization with influenza vaccine. Uakhak Hoeji. 59: 1-5, 2015).
산수유는 늦은 가을과 초겨울에 과피가 빨간색으로 변한 산수유 나무(Cornus officianalis)의 열매를 따서 씨를 뽑아내고 햇볕에 말린 것을 말한다. 한의학에서의 산수유는 맛이 시고 성질은 약간 따뜻하며 간경, 신경에 좋고, 이뇨작용, 혈압강하작용, 단백질의 소화를 돕는 작용, 항암 및 항균작용 등이 있는 것으로 보고되고 있다. 성분으로는 다양한 유기산과 morronoside, loganin, sweroside와 같은 iridoid 배당체, tannin류 등이 있으며, 활성 산소종을 감소시켜 산화적 스트레스를 완화시키며, 지질 합성 관련 분자의 발현을 억제하여 지질대사에도 작용하는 것으로 보고되었고 또한 인지력 향상에도 효과가 있는 것으로 알려져 있다(Park E. B., Kim H. S., Shin S. Y., Ji I. A., Kim J. H., Kim S. G., Yoo B. H., Kim B. W., Kwak I. S., Kim M. M., Chung K. T., Antioxidative activity of Cornus officianalis extracts obtained by four different extraction techniques. J. Life Sci. 22: 1507-1514, 2012).Cornus syrup is a late-fall and early-winter fruit that turns red in the perilla ( Cornus officianalis ) and extracts the seeds from the seeds of the dried fruits. In the Oriental medicine, corn oil is tasted, its properties are slightly warm, and it is reported that it has liver, nervousness, diuretic action, hypotensive action, action to help digestion of protein, anticancer and antibacterial action. These compounds include various organic acids and iridoid glycosides such as morronoside, loganin, and sweroside, and tannins. They reduce oxidative stress by reducing active oxygen species, inhibit the expression of lipid synthesis-related molecules, and act on lipid metabolism (Kwak, IS, Kim, MM, Chung, KT). Antioxidative activity of Cornus is known to be effective in improving cognitive function Extracts of officianalis obtained by four different extraction techniques. J. Life Sci. 22: 1507-1514, 2012).
구기자(Lycii fructus)는 구기자나무(Lycium chinensis Miller)의 열매로 성분으로는 carotenoid, choline, melissic acid, zeaxanthin, physalin, betaine, β-sitosterol, vitamin B1, rutin과 불포화지방산 등 기능성 성분이 다량 함유되어 있으며 항산화 효과, 항균효과, 간 기능 개선, 혈압강하 및 항당뇨 효과, 면역증진 효과 등의 효능이 알려지고 있다(Lee K. A., Antioxidative and anti-diabetes activity, and free amino acid and mineral contents of beverage with Gugija(Lycii fructus) extracts. Korean J. Food Cook Sci. 31: 207-213, 2015).Gugija ( Lycii fructus ) was isolated from Lycium chinensis Miller) contains a large amount of functional ingredients such as carotenoids, choline, melissic acid, zeaxanthin, physalin, betaine, β-sitosterol, vitamin B1, rutin and unsaturated fatty acids. Antioxidant effect, antibacterial effect, , blood pressure lowering and anti-diabetic effects, it is known the efficacy of such immune enhancing effect (Lee KA, Antioxidative and anti-diabetes activity, and free amino acid and mineral contents of beverage with Gugija (Lycii fructus ) extracts. Korean J. Food Cook Sci. 31: 207-213, 2015).
누에(Bombyx mori)는 누에나방과(Bombycidae)에 속하는 누에나방의 유충으로 소아의 경기를 치료하거나 기생충 제거하는데 효과가 있다고 기록되고 있으며 보고되고 있는 연구에 따르면 혈당강하효과(Chung S. H., Ryu J. H., Kim I. J., Blood glucose lowering of silkworm. J. KyungHee Pharm. 24: 95-100, 1996; Pyu K. S., Lee H. S., Chung S. H., Kang P. D., An activity of lowering blood-glucose levels according to preparative conditions of silkworm power. Kor. J. Seric Sci. 39: 79-85, 1997), 기관지의 점액분비 촉진효과(Kang Y. K., Lim H. B., Son H. O., Lee Y. G., Lee D. W., Nam S. H., Effect of silkworm-extract on mucus secretion in rat tracheobronchial lumen. Kor. J. Entomol. 30: 71-75, 2000), 파킨슨병 동물모델에서 신경전달물질인 도파민의 보호효과 등 누에의 약리학적인 효능(Kang Y. K., Oh H. S., Cho Y. H., Kim Y. J., Han Y. G., Nam S. H., Effect of a silkworm extract on dopamine and monoamine oxidase-B activity in an MPTP-induced Parkinson's disease model. Lab. Anim. Res. 26: 287-292, 2010) , 항당뇨 효과(Kim E. J., Kim S. H., Kim S. M., Development of a beverage using the extracts from Bombyx mori L., Morus alba L., Dioscoreae rhuzome and Inonotus obliquus. Kor. J. Food Preserv. 18: 844-852, 2011) 등이 증명된 바 있다.Silkworm ( Bombyx mori ) is a larva of the silkworm moth (Bombycidae), which is reported to be effective in treating children's parasites and eliminating parasites. According to a reported study, the hypoglycemic effect (Chung SH, Ryu JH, Kim IJ, Blood glucose lowering of silkworm. J. KyungHee Pharm. 24: 95-100, 1996; Pyu KS, Lee HS, Chung SH, Kang PD, An activity of lowering blood glucose levels according to preparatory conditions of silkworm power. (Mucus secretion in rat tracheobronchial lumen), which has been shown to induce mucin secretion in bronchial tissues (Seric Sci., 39: 79-85, 1997) (Kang YK, Oh HS, Cho YH, Kim YJ, Han YG, Park JH, Park JH, , Nam SH, Effect of a silkworm extract on dopamine and monoamine oxidase-B activity in an MPTP-induced Parkinson's disease model. (Kim EJ, Kim SH, Kim SM, Dev elopement of a extract of extracts from Bombyx mori L., Morus alba L., Dioscoreae rhuzome and Inonotus obliquus. Kor. J. Food Preserv. 18: 844-852, 2011).
복령(Poria cocos Wolf)은 소나무를 벌채한 후, 4~5년이 경과한 뒤 땅속의 뿌리에서 기생하는 다공균과에 속한 진균인 복령의 균핵이다. 주성분은 전분 및 탄수화물, 수분, 지방, 단백질 및 무기질이며, 이뇨작용, 만성위염과 복통, 혈당강하작용, 헐허 등에 효과가 있다고 하여 한약 재료 및 생약제로 많이 이용되고 있다(Yun H. J., Cha H. M., Kim S. W., Shin W. C., Effects of the extract of hoelen on serum lipid profiles in mice. J. Kor. Soc. Food Sci. Nutr. 35: 1005-1009, 2006). Poria cocos Wolf is the sclerot of the bacillus, which is a fungus belonging to the genus Pseudomonas aeruginosa, which parasitizes in the root of the ground after 4 to 5 years after cutting the pine tree. The main ingredients are starch and carbohydrate, water, fat, protein and minerals, and are widely used as herbal medicines and herbal medicines because of their effects on diuretic action, chronic gastritis and abdominal pain, hypoglycemic effect and malaise (Yun HJ, Cha HM, Kim SW, Shin WC, Effects of the extracts of hoelen on serum lipid profiles in mice, J. Kor. Soc. Food Sci. Nutr. 35: 1005-1009, 2006).
옥타코사놀은 쌀겨와 및의 씨눈, 사탕수수 등에 극소량 함유되어 있는 생리활성 물질로서 근력, 근지구력, 순발력, 민첩성 향상, 스트레스 저항 강화, 기초대사율 향상, 심폐지구력 향상, 피로감 감소, 지방 이용률 증가, 글리코겐 축적과 촉진에 효과가 있는 성분이며 계절에 따라 1회의 휴식 없이 수천 킬로를 서식지로 이동하는 철새의 중요한 에너지원이다(Kato S. K., Hasegawa S., Nagasawa J., Nagasaki A., Eguchi M., Hamatani K., Octacosanol affects lipid metabolism in rats fed on a high-fat diet. Br. J. Nurt. 73: 433-441, 1995). 옥타코사놀 섭취는 최대산소섭취량 증가 및 심장에 대한 부담감 감소와 혈액응고 작용과 심장기능을 강화시켜 지구력을 향상시키고, 항고지혈증 예방 및 심장질환에 효과적이라고 보고되고 있다(Mas R., Castano G., Illnait J., Fernandez L., Fernandez J., Aleman C., Pontigas V., Escay M., Effects of policosanol in patients with type II hyercholest-terolemia and additional coronary risk factors. Clin. Pharmacol. Ther. 65: 439-447, 1999).Octacosanol is a physiologically active substance which is contained in rice bran, syrup, sugar cane and so on in a very small amount. It is a physiologically active substance including muscle strength, muscle endurance, (Kato SK, Hasegawa S., Nagasawa J., Nagasaki A., Eguchi M., and Hamatani K.), which is an effective energy source for migratory birds. , Octacosanol affects lipid metabolism in rats fed on a high-fat diet (Br J. Nurt., 73: 433-441, 1995). Octacosanol intake has been reported to increase maximal oxygen uptake and reduce heart burden, enhance blood clotting and cardiac function, improve endurance, and prevent hyperlipidemia and heart disease (Mas R., Castano G., Illnait J., Fernandez L., Fernandez J., Aleman C., Pontigas V., Escay M., Effects of policosanol in patients with type II hyercholest-terolemia and additional coronary risk factors.Clin.Pharmacol. Ther. 65: 439- 447, 1999).
이와 같이 성기능 강화 및 체질 개선 효능이 있는 국내외의 천연식물인 홍삼과 마카 및 천연발효물에 대한 성기능 조절효과를 연구하는 것은 새로운 건강 기능성식품의 개발과 관련하여 상당히 유익한 시도로 사료된다. 이에 대한 연구가 수행된다면 천연 복합물에 대한 성기능 상승효과 여부를 검증할 수 있으며, 향후에는 남성의 성기능 증진제인천연 viagra를 개발할 수 있을 것으로 사료된다. The study of the sexual function control effect of red ginseng, maca, and natural fermented products, which are natural and natural ginseng enhancing effect of sexual function and constitution improvement, is considered to be a very beneficial attempt for the development of a new health functional food. If this study is carried out, it can be verified whether or not the sexual function of the natural complex is increased. In the future, it will be possible to develop a natural viagra which is a male sexual enhancement agent.
이를 통하여 일시적인 성기능 개선과 부작용이 따르는 의약품과는 차별화되는 홍삼·마카 이외에 천연 복합물은 인체에 무해하며, 성기능 개선뿐만 아니라 건강기능식품으로서의 생리기능 조절효과도 제공할 수 있을 것이다. In addition, the natural complexes are harmless to the human body in addition to the red ginseng and maca, which are different from the drugs which have temporal sexual function improvement and side effects, and can also provide physiological function control effect as a health functional food as well as sexual function improvement.
또한, 식품학적 측면에 있어 응용 가치가 충분하다고 생각되나 자연 발효 및 숙성과 유효성분을 다량 함유시킨 발효에 의한 성기능 개선에 관한 연구는 이루어진 바가 없으므로 이러한 식품 조성물의 개발을 통해 성기능 장애의 개선 또는 치료의 효과를 나타내는 조성물을 제공할 수 있을 것으로 기대된다.In addition, although it is considered that the application value is sufficient in terms of foodstuffs, there have been no researches on natural fermentation and aging and improvement of sexual function by fermentation containing a large amount of active ingredient. Therefore, Lt; RTI ID = 0.0 > of < / RTI >
한편 발효는 최근 생물전환기술(bioconversion)이라는 명칭으로 활용되는 식품가공기술로 항암, 콜레스테롤 저하, 혈압강하, 혈전저해, 설사 방지 등의 생균제 효과에 대한 연구 결과가 계속 발표되고 있는 차세대 기술이다. 세계보건기구 산하 Codex에서는 유전자재조합 미생물을 이용한 생균제 사용에 대한 규정을 마련하기로 합의한 바 있어 안전성을 인정받은 발효 미생물은 21세기 바이오 산업의 핵심이 될 수 있으며, 이를 이용한 미생물의 산업적 가능성은 앞으로 하나의 새로운 산업분야로 자리 잡을 전망이다. On the other hand, fermentation is a next-generation technology in which research results on the effects of probiotics such as anticancer, cholesterol lowering, blood pressure lowering, blood clotting inhibition and diarrhea prevention are continuously announced by the food processing technology called bioconversion. The Codex affiliated with the World Health Organization has agreed to establish provisions for the use of probiotics using genetically modified microorganisms. Fermented microorganisms recognized as safe can be the core of the 21st century bio-industry. Is expected to become a new industrial field.
전통발효식품에 관여하는 고초균은 호기성 균으로 다양한 가수분해효소를 생산하면서 콩 발효식품에 크게 기여하고 있다. 발효과정을 거치면서 고초균에 의해 단백질 가수분해 효소, 탄수화물 가수분해 효소, 혈전분해 효소, 기능성 펩타이드 및 고분자 점질물 등의 생리활성물질을 생산된다(Kwon H. Y., Kim Y. S., Kwon G. S., Kwon C. S., Sohn H. Y., Isolation of immuno-stimulating strain Bacillus pumilus jb-1 from Chungkook-jang and fermentation characteristics of jb-1. Kor. J. Microbial. Biotechnol. 32: 291-296, 2004). Bacillus, which is involved in traditional fermented food, is a aerobic bacterium that produces various hydrolytic enzymes and contributes greatly to soybean fermented foods. After the fermentation process, a physiologically active substance such as a protease, a carbohydrate hydrolase, a thrombolytic enzyme, a functional peptide and a polymer viscous substance is produced by Bacillus subtilis (Kwon HY, Kwon GS, Kwon CS, Sohn HY , Isolation of immuno-stimulating strain Bacillus pumilus jb-1 from Chungkook-jang and fermentation characteristics of JB-1. Kor J. Microbial. Biotechnol. 32: 291-296, 2004).
발효숙성 시 고초균이 생산하는 효소에 의하여 단백질과 당질이 분해되어 levan form fructan과 glutamic acid가 중합된 poly-γ-glutamic acid(PGA)로 구성된 끈끈한 점질물이 생성되며(Youn H. K., Choi H. S., Hur S. H., Hong J. H., Antimicrobial activities of viscous substance form Chongkukjang fermented with different Bacillus spp. J. Fd. Safety 16: 188-193, 2001), 이러한 점질물은 발효제품의 품질특성에 중요한 영향을 미친다.When fermented, the enzyme produced by Bacillus subtilis degrades the proteins and saccharides, resulting in a sticky viscous substance composed of poly-γ-glutamic acid (PGA) polymerized with levan form fructan and glutamic acid (Youn HK, Choi HS, , Hong JH, Antimicrobial activities of viscous substance form Chongkukjang fermented with different Bacillus spp., J. Fd. Safety 16: 188-193, 2001), these stomachs have an important influence on the quality characteristics of the fermented product.
특히 PGA는 미생물 고분자물질의 일종으로 면역증진 효과, 항암효과 등의 생리활성기능을 가지고 있으며 또한 탄수화물과 단백질을 주로 분해하여 생성되는 생리활성 물질은 제품의 품질에 결정적인 영향을 줄뿐만 아니라 생물전환기술에 따른 다당류체, 올리고당, 아미노산류, 펩타이드류, 유기산류, 폴리페놀류 등의 유효 성분의 생성 및 증가에 따라 다양한 생리활성을 나타내는 것으로 잘 알려져 있다(Lee T. S., Choi J. Y., Volatile flavor components in mash of Takju prepared by suing Aspergillus kawachii nuruks. Kor. J. Food Sci. Technol. 37: 944-950, 2005). In particular, PGA is a type of microbial polymer material that has physiological functions such as immunity enhancement and anticancer effects, and physiologically active substances produced by mainly decomposing carbohydrates and proteins have a decisive influence on the quality of products, (Lee TS, Choi JY, Volatile Flavor Components in Mash of Lactic Acid), which is known to exhibit various physiological activities depending on the production and increase of effective components such as polysaccharides, oligosaccharides, amino acids, peptides, organic acids and polyphenols Takju prepared by suing Aspergillus kawachii nuruks. Kor J. Food Sci. Technol., 37: 944-950, 2005).
본 발명자들은 재래 청국장으로부터 분리한 수종의 균주를 단일균주로 사용하여 항돌연변이 활성, 점질물, 유리아미노산 함량 및 관능검사를 행하여 우수균주로 Bacillus licheniformis를 선발하였으며(Lee M. Y., Quality and functional characteristics of chungkukjang fermented by Bacillus sp. isolated from commercial products. MS Thesis. Catholic University of Daegu. p 1-62, 2005), Bacillus licheniformis를 발효산물로 하여 생리활성을 증대시킨 기술을 확보한 바 있다(대한민국 등록특허공보 10-1204875호). The present inventors selected Bacillus licheniformis as an excellent strain by carrying out an antimutagenic activity, a viscous substance, a free amino acid content and a sensory test by using several strains isolated from Korean traditional cheonggukjang as a single strain (Lee, MY, Quality and functional characteristics of chungkukjang fermented by Bacillus sp. isolated from commercial products . MS Thesis. Catholic University of Daegu. p 1-62, 2005), is a bar to secure the technologies that increase the physiological activity of Bacillus licheniformis in fermentation products (Republic of Korea Patent Application 10 1204875).
본 발명은 상기와 같은 종래기술의 과제를 해결하기 위하여 안출된 것으로, 홍삼 분말 및 발효 혼합 분말로 이루어진 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물을 통해 간 해독, 활성산소 소거, 알코올성 발기부전, 성기능 개선의 효과를 나타내는 기능성 식품 조성물을 제공하는 것을 그 목적으로 한다.Disclosure of Invention Technical Problem [8] The present invention has been made to solve the above problems of the prior art, and it is an object of the present invention to provide a functional food composition containing red ginseng fermented mixed composition comprising red ginseng powder and fermented mixed powder, It is an object of the present invention to provide a functional food composition showing an effect of improvement.
특히, 한국산 홍삼 및 천연 발효 분말로 이루어진 조성물에 대한 혼합 식이를 2-bromopropane (고환손상 유도제)을 처리한 흰쥐의 고환과 타 장기에 대한 영향 및 산화적 손상 정도를 통해 검증함으로써 성기능 개선의 효과가 입증된 기능성 식품 조성물을 제공하는 것을 그 목적으로 한다.In particular, the effect of improving sexual function was examined by examining the effects of oxidative damage on the testis and other organs of rats treated with 2-bromopropane (testosterone-inducing agent) for the mixed diet of Korean red ginseng and natural fermented powder It is an object of the present invention to provide a proven functional food composition.
또한, 장기적으로 에탄올을 투여하여 알코올 대사와 활성산소종(ROS) 생성계 및 제거계 효소의 활성변동과 간 조직 손상의 지표를 관찰하여 천연 발효 물질을 이용한 성기능 개선 및 알코올에 의한 발기부전 예방, 환경호르몬 및 산화적 스트레스에 의한 개선효과 있는 남성 건강 및 성기능 증진용 건강 기능성 식품 조성물을 제공하는 것을 그 목적으로 한다.In addition, long-term ethanol was administered to observe the changes in the activity of alcohol metabolism, ROS production system and elimination enzyme, and the index of liver tissue damage, thereby improving sexual function using natural fermented substances, preventing erectile dysfunction caused by alcohol, It is an object of the present invention to provide a health functional food composition for enhancing male health and sexual function which is improved by environmental hormones and oxidative stress.
상기와 같은 과제를 해결하기 위한 본 발명의 기능성 식품 조성물은 홍삼 분말 및 발효 혼합 분말을 포함하는 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물로서, 상기 발효 혼합 분말은 마카, 다미아나, 호박씨, 대두, 생강, 동충하초, 산수유, 구기자, 누에, 및 복령으로 구성되는 것을 특징으로 한다. 또한, 상기 발효 혼합 분말은 옥타코사놀을 추가적으로 할 수 있다.The functional food composition of the present invention for solving the above problems is a functional food composition comprising a red ginseng fermented mixed composition comprising red ginseng powder and fermented mixed powder, wherein the fermented mixed powder is selected from the group consisting of maca, damiana, pumpkin seed, Ginger, Chinese caterpillar fungus, corn syrup, gugija, silkworm, and gypsum. In addition, the fermentation mixed powder may further comprise octacosanol.
본 발명에서 상기 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물은 마카, 다미아나, 호박씨, 대두, 생강, 동충하초, 산수유, 구기자, 누에, 및 복령으로 구성된 발효 혼합 분말의 원료를 전처리하는 전처리 단계; 상기 전처리된 원료를 발효 미생물과 혼합하여 숙성하여 발효 혼합 분말을 제조하는 단계; 상기 발효 혼합 분말 및 홍삼 분말을 혼합하여 홍삼 발효 혼합 분말을 제조하는 단계; 상기 홍삼 발효 혼합 분말 중 일부를 추출 및 농축하여 혼합 발효 추출 농축액을 제조하는 단계; 상기 홍삼 발효 혼합 분말에 상기 혼합 발효 추출 농축액을 분사한 후 건조하여 홍삼 혼합 조성물을 제조하는 단계를 포함하는 것을 특징으로 한다.In the present invention, the functional food composition comprising the red ginseng fermented mixed composition comprises a pretreatment step of pretreating a raw material of a fermentation mixed powder composed of maca, damiana, pumpkin seed, soybean ginger, cordyceps, acid fermented milk, gugija, silkworm, Mixing the pretreated raw material with a fermenting microorganism and aging the mixture to prepare a fermentation mixed powder; Mixing the fermentation mixed powder and the red ginseng powder to prepare a red ginseng fermentation mixed powder; Extracting and concentrating a part of the red ginseng fermentation mixed powder to prepare a concentrated fermentation extract concentrate; Mixing the red ginseng fermentation mixed powder with the mixed fermentation extraction concentrate and drying the mixture to prepare a red ginseng mixed composition.
이때, 상기 전처리 단계는 상기 원료를 각각 가압살균, 로스팅, 급속 동결 건조한 후 이를 분쇄하는 단계로 이루어지며, 상기 홍삼 발효 혼합 조성물을 제조하는 단계는 상기 홍삼 발효 혼합 분말에 대하여 상기 혼합 발효 추출 농축액 10 중량부를 분사한 후, 함수율이 5% 이하가 되도록 건조하는 것을 특징으로 한다.The preparation of the fermented red ginseng composition comprises mixing the red ginseng fermented mixed powder with the mixed
본 발명에 따른 기능성 식품 조성물은 홍삼 분말 및 발효 혼합 분말로 이루어진 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물을 통해 간 해독, 활성산소 소거, 알코올성 발기부전, 성기능 개선의 효과를 나타낸다.The functional food composition according to the present invention exhibits the effects of hepatic detoxification, active oxygen scavenging, alcoholic erectile dysfunction and sexual function improvement through a functional food composition comprising red ginseng fermented mixed composition comprising red ginseng powder and fermented mixed powder.
또한, 한국산 홍삼 및 천연 발효 분말을 원료로 함으로써 알코올 대사와 활성산소종(ROS) 생성계 및 제거계 효소의 활성변동과 간 조직 손상에 대한 효과를 통해 천연 발효 물질을 이용한 성기능 개선 및 알코올에 의한 발기부전 예방, 환경호르몬 및 산화적 스트레스에 의한 개선효과 있는 남성 건강 및 성기능 증진용 건강 기능성 식품 조성물을 제공할 수 있다.In addition, by using Korean red ginseng and natural fermented powder as raw materials, the effect of alcohol metabolism, active oxygen species (ROS) production system and elimination enzyme activity on liver tissue damage and improvement of sexual function using natural fermented substance and alcohol It is possible to provide a health functional food composition for improving male health and sexual function, which is effective for prevention of erectile dysfunction, environmental hormone and oxidative stress.
도 1은 본 발명의 일 실시예에 따른 기능성 식품 조성물을 제조하는 과정을 나타낸 공정도이다.
도 2는 홍삼 추출물(BR), 홍삼 혼합 조성 추출물(BRM), 홍삼 발효 혼합 추출물(BRFM)을 함유하는 식이로 흰쥐를 4주간 사육하는 동안 만성적 에탄올 투여에 의해 발기부전을 유도하였을 때, 혈청 알라닌 아미노 전이효소 활성(a) 및 아스파르테이트 아미노 전이효소 활성(b)을 나타낸 그래프이다.
도 3은 홍삼 추출물(BR), 홍삼 혼합 조성 추출물(BRM), 홍삼 발효 혼합 추출물(BRFM)을 함유하는 식이로 흰쥐를 4주간 사육하는 동안 만성적 에탄올 투여에 의해 발기부전을 유도하였을 때, 간 조직의 글루타치온 함량(a), 과산화지질 함량(b) 및 중성지방 함량(c)을 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a process diagram showing a process for producing a functional food composition according to an embodiment of the present invention; FIG.
FIG. 2 shows that when erectile dysfunction was induced by chronic ethanol administration during 4 weeks of rats fed with red ginseng extract (BR), red ginseng mixed composition extract (BRM), and red ginseng fermented mixed extract (BRFM) (A) and aspartate aminotransferase activity (b).
FIG. 3 shows that when erectile dysfunction was induced by chronic ethanol administration during 4 weeks of rats fed with red ginseng extract (BR), red ginseng mixed composition extract (BRM) and red ginseng fermented mixed extract (BRFM) (A), lipid peroxide content (b), and triglyceride content (c).
이하 도면을 참조하여 본 발명을 보다 상세히 설명한다. 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Hereinafter, the present invention will be described in more detail with reference to the drawings. The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may appropriately define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.
본 발명에서 사용되는 용어인 홍삼 발효 혼합 조성물은 홍삼 분말과 발효 혼합 분말을 혼합하되, 혼합 발효 추출 농축액을 부가한 것을 가리키는 용어이다.The term "red ginseng fermented mixed composition" as used in the present invention refers to a mixture of red ginseng powder and fermented mixed powder, in which a mixed fermentation extract concentrate is added.
또한, 발효 혼합 분말은 천연물 분말을 혼합하되 이를 발효 미생물을 배합하여 발효시킴으로써 제조한 혼합 분말을 가리키는 용어이며, 홍삼 분말은 홍삼을 분쇄하여 분말화한 것을 가리키는 용어이다.The term "fermented mixed powder" refers to a mixed powder prepared by mixing natural product powder with fermenting microorganism and fermenting it. The term "red ginseng powder" refers to pulverized red ginseng powder.
또한, 혼합 발효 추출 농축액은 홍삼 분말과 발효 혼합 분말을 혼합하여 추출 및 농축과정을 거쳐 제조된 추출 농축액을 가리키는 용어이다.Also, the mixed fermentation extracted concentrate refers to an extract concentrate prepared by mixing red ginseng powder and fermented mixed powder and extracting and concentrating.
또한, 홍삼 발효 혼합 분말은 상기 발효 혼합 분말과 상기 홍삼 분말을 혼합하여 제조한 혼합 분말을 가리키는 용어이다.The term "red ginseng fermentation mixed powder" refers to a mixed powder prepared by mixing the fermentation mixed powder and the red ginseng powder.
본 발명은 홍삼 분말 및 발효 혼합 분말을 포함하는 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물에 관한 것이다.The present invention relates to a functional food composition comprising a red ginseng fermented mixed composition comprising red ginseng powder and fermented mixed powder.
본 발명에서 상기 발효 혼합 분말은 마카, 다미아나, 호박씨, 대두, 생강, 동충하초, 산수유, 구기자, 누에, 및 복령으로 구성된다.In the present invention, the fermented mixed powder is composed of maca, damiana, pumpkin seed, soybean, ginger, cordyceps, corn oil, goji, silkworm, and bamboo.
상기 마카, 다미아나, 호박씨, 대두, 생강, 동충하초, 산수유, 구기자, 누에, 및 복령에 대해서는 공지기술을 통해 알려진 바와 같이 다양한 효능을 나타내는 것으로서 이를 병용함으로써 성기능 개선의 효과를 나타낼 수 있다.The above-mentioned maca, damiana, pumpkin seed, soybean, ginger, cordyceps, corn oil, gugija, silkworm, and bamboo are known to have various effects as well known in the art and can be used to improve sexual function.
본 발명에서 발효 혼합 분말은 상기 10가지 성분을 모두 사용할 때 그 효과를 나타낼 수 있다. 이는 종래기술에서도 기술한 바와 같이 상기 10가지 성분들 각각의 효과뿐만 아니라 이를 병용함으로써 얻어지는 상승된 효과를 얻기 위해 다양한 천연물 성분 중 선택한 것으로 천연물을 단순히 혼합한 것과는 차이가 있는 것이다.In the present invention, the fermentation mixed powder can exhibit its effect when all of the above ten components are used. This is because, as described in the prior art, not only the effect of each of the above-mentioned 10 components but also the selection of various natural ingredients in order to obtain an elevated effect obtained by using them in combination, is different from a simple mixture of natural products.
상기 10가지 성분 중 1 또는 2 성분을 제외한 경우, 예를 들어, 마카, 호박씨를 제외하거나, 생강, 구기자를 제외한 경우에는 본 발명에서 목적하는 성기능 개선 등의 특유한 효과를 충분히 얻을 수 없는 것으로 파악되었다.It was found that when the one or two components out of the above 10 components are excluded, for example, except for maca, pumpkin seed, ginger, and ginger, the specific effects such as the sexual function improvement aimed at in the present invention can not be sufficiently obtained .
즉, 발효혼합분말의 원료로 사용되는 각각의 생약제는 약학적으로 개별적 효능은 뛰어나나 본 개발에서 발명하고자 하는 간 해독, 활성산소 소거 및 알코올성 발기부전, 성기능 개선의 효능을 나타내는 기능성 조성물을 제공하는 것을 목적으로 배합 후 발효 가공하여 그 효능을 극대화시킴에 따라 단독이 아닌 복합 구성으로 사용한다. That is, each of the herbal medicine used as a raw material of the fermentation mixed powder is excellent in pharmaceutical efficacy, but provides a functional composition exhibiting the effects of liver detoxification, active oxygen scavenging, alcoholic erectile dysfunction and sexual function improvement, For the purpose of maximizing the efficacy of the fermentation process after mixing, it is used as a non-single complex composition.
또한, 상기 발효 분말은 옥타코사놀을 추가적으로 포함할 수 있다. 주요한 에너지원인 사탕수수에서 추출된 옥타코사놀은 상기 홍삼 혼합 조성물의 제조 과정에 균등하게 함유 될 수 있도록 분사(액체) 또는 배합(부말)의 공정으로 균질화 한다. In addition, the fermentation powder may further comprise octacosanol. Octacosanol extracted from sugarcane, which is a main energy source, is homogenized by a process of injection (liquid) or compounding (boiling) so that it can be uniformly contained in the manufacturing process of the red ginseng mixed composition.
본 발명에 따른 기능성 식품 조성물은 도 1에 도시된 바와 같은 공정에 의해 제조될 수 있다.The functional food composition according to the present invention can be produced by a process as shown in Fig.
즉, 도 1에 도시된 바와 같이, 마카, 다미아나, 호박씨, 대두, 생강, 동충하초, 산수유, 구기자, 누에, 및 복령으로 구성된 혼합 발효 분말의 원료를 전처리하는 전처리 단계; 상기 전처리된 원료를 발효 미생물과 혼합하여 숙성하여 혼합 발효 분말을 단계; 상기 혼합 발효 분말을 추출 및 농축하여 혼합 발효 추출 농축액을 제조하는 단계; 상기 혼합 발효 분말과 홍삼 분말을 혼합한 혼합 분말에 상기 혼합 발효 추출 농축액을 분사한 후 건조하여 홍삼 혼합 분말을 제조하는 단계를 포함하여 제조된다.That is, as shown in FIG. 1, a pretreatment step of pretreating raw materials of mixed fermentation powders composed of maca, damiana, pumpkin seed, soybean, ginger, cordyceps, corn oil, gougia, silkworm, and bamboo; Mixing the pretreated raw material with a fermentation microorganism and aging the mixture to prepare a mixed fermentation powder; Extracting and concentrating the mixed fermentation powder to prepare a concentrated fermentation extract concentrate; Mixing the mixed fermentation powder with the red ginseng powder, spraying the mixed fermentation extraction concentrate, and drying the mixture to prepare a red ginseng mixed powder.
이때, 상기 전처리 단계는 상기 원료를 스티밍, 로스팅, 급속 동결 건조한 후 이를 분쇄하는 단계로 이루어지며, 상기 홍삼 혼합 분말을 제조하는 단계는 상기 혼합 발효 분말과 상기 홍삼 분말을 혼합한 분말에 대하여 상기 혼합 발효 추출 농축액 10 중량부를 분사한 후, 함수율이 5% 이하가 되도록 건조하는 것을 특징으로 한다.The step of preparing the red ginseng mixed powder may include a step of mixing the powder obtained by mixing the red ginseng powder with the red ginseng powder, 10 parts by weight of the concentrated fermentation broth concentrate is sprayed and then dried so that the water content becomes 5% or less.
본 발명에 따른 홍삼 발효 혼합 조성물은 분말인 상태로 음용할 수도 있고, 정제, 환제, 산제, 과립제, 캡슐제 등의 고형 제제나, 현탁제, 내용액제, 유제, 시럽제 등의 액상 제제로 가공할 수도 있다. 따라서 본 발명에서 상기 기능성 식품 조성물은 상기 홍삼 발효 혼합 조성물을 주성분으로 하되 용도에 따라 다양한 첨가제를 적절히 배합하여 제품화할 수 있는 것이다.The fermented red ginseng mixed composition according to the present invention may be used in the form of a powder or as a solid preparation such as a tablet, a pill, a powder, a granule, a capsule, or a liquid preparation such as a suspension, a solution, an emulsion or a syrup It is possible. Therefore, in the present invention, the functional food composition can be produced by mixing the red ginseng fermented mixed composition as a main component and various additives according to the application.
이하 실시예를 통해 본 발명의 기능성 식품 조성물 및 이의 제조방법에 대해 자세히 설명한다. Hereinafter, the functional food composition of the present invention and its preparation method will be described in detail by way of examples.
홍삼은 6년근 수삼으로 제조한 분말제품(150 mesh)을 금산농협에서 구입한 후 4℃에 보관하면서 사용하였다. 마카, 다미아나, 호박씨, 대두, 생강, 동충하초, 산수유 ,구기자, 누에, 복령 및 옥타코사놀은 농가 및 원료 상에서 구입하였다. 균주로는 재래청국장으로부터 우수균주로 선발된 Bacillus licheniformis 균주(Lee M. Y., Quality and functional characteristics of chungkukjang fermented by Bacillus sp. isolated from commercial products. MS Thesis. Catholic University of Daegu. p 1-62, 2005)를 사용하였다. 효능분석에 사용한 시약은 일반 특급시약을 사용하였다.Red ginseng was purchased from Jinshan Agricultural Cooperative Federation and stored at 4 ℃. Maca, Damiana, pumpkin seed, soybean, ginger, cordyceps, corn oil, gougie, silkworm, bokyeong and octacosanol were purchased from farmers and raw materials. Bacillus licheniformis strains isolated from Korean traditional cheonggukjang were identified as Bacillus licheniformis strain (Lee MY, Quality and functional characteristics of chungkukjang fermented by Bacillus sp. Isolated from commercial products, MS Thesis, Catholic University of Daegu, pp. 1-62, 2005) Respectively. The reagents used for the efficacy analysis were the standard reagents.
사용된 재료의 명칭과 사용부위 및 함량은 표 1과 같다.Table 1 shows the name of the materials used, the site of use, and the content.
각각의 재료의 함량범위는 본 발명에서 목적하는 성분들의 병용에 따른 성기능 개선의 효과를 얻기 위해 최적화된 것으로서, 각각의 성분이 상기 범위를 벗어나 지나치게 많거나 지나치게 적은 경우 상기 10가지 성분을 모두 발효 혼합 분말의 성분으로 사용한다고 하더라도 상대적으로 성기능 개선 등의 효과가 충분히 발현되지 않는 것으로 파악되었다.The content ranges of the respective materials are optimized to obtain the effect of improving the sexual function according to the combination of the components of the present invention. When the respective components are out of the above range and excessively or excessively small, Even when used as a powder component, it was found that effects such as sexual function improvement were not sufficiently manifested.
상기 표 1에 기재된 재료를 사용하여 본 발명의 기능성 식품 조성물은 다음과 같이 제조되었다.Using the ingredients listed in Table 1 above, the functional food composition of the present invention was prepared as follows.
제 1단계 (원료의 전처리)The first step (pretreatment of raw material)
가공 소재에 대하여 용해성 및 흡수성 등 가공 적성 향상을 부여하기 위하여 각각의 재료를 선별, 세척, 증자한 다음 건조하였다. 각각의 원료는 steaming(증자, 가압살균 autoclave; 1~5분, 95~100℃) 처리를 하는데, 이때 적정 고압증기로 압력을 인가하여 살균처리 및 제거되지 못한 불순물을 제거함과 동시에 위생성 부여 및 물성 변화로 안전성 및 가공적성(습윤성, 침강성, 분산성 및 용해성)을 향상시켰다.Each material was selected, washed, and then dried to give improved processing aptitude such as solubility and water absorbability. Each raw material is treated by steaming (steam, autoclave for 1 ~ 5 minutes, 95 ~ 100 ℃), where pressure is applied with appropriate high pressure steam to remove sterilization treatment and impurities that have not been removed, Changes have improved safety and processability (wettability, sedimentation, dispersibility and solubility).
다음으로 갈변효소를 불활성화시키고, 원 재료의 맛, 향 및 저장성 증진을 위하여 roasting(볶음, 로스팅기; 120~220℃, 3~7분)처리를 한 다음 영양분 손실을 최소화되도록 급속 동결건조 시켰다. Next, roasting (roasting, roasting machine; 120 ~ 220 ℃, 3 ~ 7min) was performed to inactivate the browning enzyme and rapid freeze-drying to minimize the loss of nutrients in order to improve taste, .
건조물은 유용성분 추출 및 발효의 촉진을 증대시키기 위하여 1차적으로 파쇄기로 파쇄를 한 뒤 미세분쇄기로 2차 파쇄하여 120 메쉬의 분말을 얻었다.The dried material was first pulverized with a crusher and then crushed second by a fine crusher in order to increase the extraction of useful components and the promotion of fermentation, thereby obtaining a 120 mesh powder.
제 2단계 (배합 및 발효 미생물을 혼합 및 숙성하는 단계)The second step (mixing and aging of the compounding and fermenting microorganisms)
마카 11 중량%, 다미아나 17 중량%, 호박씨 7 중량%, 대두 11 중량%, 생강 7 중량%, 동충하초 16 중량%, 구기자 8 중량%, 누에 8 중량%, 산수유 9 중량%, 복령 6 중량%를 산화적 스트레스에 의한 개선 및 성기능 증진효능을 유도하기 위하여 등량 혼합 및 적정 비율로 고르게 혼합하였다.11 wt% of maca, 17 wt% of Damiana, 7 wt% of pumpkin seeds, 11 wt% of soybeans, 7 wt% of ginger, 16 wt% of caterpillar fungus, 8 wt% of ginger, 8 wt% of silkworm, 9 wt% Were mixed equally and mixed at an appropriate ratio in order to improve the oxidative stress and induce sexual enhancement.
유용성이 입증된 고초균(B. licheniformis)을 대량 배양하여 수세한 균체를 분말에 균일하게 접종하며 고체발효가 잘 이루어 질 수 있도록 일정량의 증류수(분말 중량의 3% 함량)를 가한 다음 일정크기로 성형하였다. 생물이 활동하기 좋은 적정온도와 습도를 유지하는 조건 등을 제공하여, 발효조건에서 고초균의 증식을 활성화시키고, 저온숙성을 통한 재료의 발효와 유용균주의 발육을 유도할 수 있게 하였다. B. licheniformis , which has been proven to be useful, is inoculated uniformly into the powder, and a certain amount of distilled water (3% of the powder weight) is added thereto so that solid fermentation can be performed. Respectively. And the conditions for keeping the appropriate temperature and humidity suitable for the activity of the organism are provided to activate the growth of Bacillus subtilis in the fermentation condition and induce the fermentation of the material and the development of the useful strain through the low temperature aging.
종균 접종 및 성형 후, 온도 35~40℃, 습도 70~90%로 24~72시간에 걸쳐 1차 발효한 후, 온도 10~25℃, 습도 45~55%로 7~14일 저온숙성을 하였다. 발효 및 숙성 후에 유용성분 추출을 증대시키기 위하여 미세분쇄기로 미세 분말화 될 수 있게 분쇄공정을 거쳤다. After inoculation and molding, primary fermentation was carried out for 24 to 72 hours at a temperature of 35 to 40 ° C and a humidity of 70 to 90%, followed by low temperature aging for 7 to 14 days at a temperature of 10 to 25 ° C and a humidity of 45 to 55% . After the fermentation and aging, the components were pulverized so as to be finely pulverized with a fine grinder in order to increase extraction of useful components.
이렇게 제조된 발효 혼합 분말은 전처리된 홍삼 분말과 혼합하여 홍삼 발효 혼합 분말을 제조하였다. 혼합비율은 홍삼 20 내지 30 중량%, 발효 혼합 분말 70 내지 80 중량%로 배합하는 것이 바람직한데, 본 실시예에서는 홍삼 25 중량%, 발효 혼합 분말 75중량%의 비율로 혼합하여 균질화시켰다.Fermented mixed powder was mixed with pretreated red ginseng powder to prepare red ginseng fermented mixed powder. The blending ratio is preferably 20 to 30% by weight of red ginseng and 70 to 80% by weight of fermented mixed powder. In this example, 25% by weight of red ginseng and 75% by weight of fermented mixed powder are mixed and homogenized.
홍삼 분말과 발효 혼합 분말의 함량비는 본 발명의 식품 조성물로부터 효과를 달성하기 위해 중요한 요인이 된다. 예를 들어, 홍삼 분말이 상기 범위를 벗어나 지나치게 많은 경우 발효 혼합 분말로 인한 상승효과를 얻을 수 없고, 반대로 홍삼 분말이 상기 범위를 벗어나 너무 적은 경우 홍삼으로 인한 상승효과를 얻을 수 없다. 또한, 각 재료의 분체 특성과 가공 시 가공적성의 향상, 유효성분의 조합에 따른 시너지 효과 등 다양한 혼합비에 대한 검토를 통해 상기와 같은 혼합비에서 균질화되는 경우 본 발명이 목적하는 효과를 달성할 수 있는 것으로 파악되었다. The content ratio of red ginseng powder and fermented mixed powder is an important factor for achieving the effect from the food composition of the present invention. For example, when the red ginseng powder is out of the above range, the synergistic effect due to the fermentation mixed powder can not be obtained. On the contrary, when the red ginseng powder is out of the above range, the synergistic effect due to red ginseng can not be obtained. In addition, it is possible to achieve the desired effect of the present invention when the mixing ratio is homogenized by examining various mixing ratios such as the powder characteristics of each material, the improvement of the processability at the time of processing, Respectively.
한편 식품에 사용되는 바실러스 속 균주는 바실러스 리체니포르미스(Bacillus licheniformis), 바실러스 푸미루스(Bacillus pumilus), 바실러스 소노렌시스(Bacillus sonorensis) 또는 바실러스 서브틸리스(Bacillus subtilis) 등을 사용할 수 있고, 바람직하게는 바실러스 리체니포르미스(Bacillus licheniformis) 또는 바실러스 서브틸리스(Bacillus subtilis)을 사용한다. Bacillus licheniformis , Bacillus pumilus , Bacillus sonorensis or Bacillus subtilis may be used as the Bacillus subtilis strain used for food, Preferably, Bacillus licheniformis or Bacillus subtilis is used.
본 발명에 사용된 발효 균주인 바실러스 리체니포르미스(Bacillus licheniformis)의 경우 재래 청국장으로부터 분리한 수종의 균주를 단일균주로 사용하였다. 또한, 항돌연변이 활성, 점질물, 유리아미노산 함량 및 관능검사를 행하여 우수균주로 선발된 균주를 본 발명의 발효물에 적용하였으므로 신체 대사기능의 증진에 효능을 발휘할 수 있다.In the case of Bacillus licheniformis , which is a fermentation strain used in the present invention, several strains isolated from Korean traditional cheonggukjang were used as a single strain. In addition, the antimutagenic activity, the viscous substance, the free amino acid content, and the sensory test can be performed to apply the strain selected as the excellent strain to the fermented product of the present invention, so that it can exert its effect on the enhancement of the body metabolism function.
제 3단계 (추출 및 농축 단계)The third step (extraction and concentration step)
다음으로, 홍삼 발효 혼합 분말로부터 유용성분의 추출을 위한 추출 및 농축 공정을 수행한다. 추출의 경우 세포 속에 잠재되어 있는 기능성 물질이나 영양분을 용매를 이용하여 밖으로 빠져나오게 하는 작업으로 열수추출, 주정추출의 2단계로 진행하여 단백질 및 천연 혼합물의 펩타이드 생성을 높인 효소 가수 분해물의 추출과 잔존 유용성분의 효율적인 추출을 가능하게 하는 것을 특징으로 한다. Next, the extraction and concentration process for extracting useful components from the fermented red ginseng powder is carried out. In the case of extraction, functional substances and nutrients that are latent in the cells are extracted from the cells using a solvent, and the process proceeds to two steps of hot water extraction and alcohol extraction to extract and hydrolyze the enzyme hydrolyzate, which increases the peptide production of protein and natural mixture Thereby enabling efficient extraction of useful components.
유용성분을 둘러싸고 있는 두꺼운 세포벽이 발효에 의해 1차적으로 분해가 되고, 열수, 주정의 순차적인 추출로 조직 내 용매의 침투가 용이해져 유용물질의 추출수율을 증대시킨다.The thick cell wall surrounding the useful ingredient is primarily decomposed by fermentation, and sequential extraction of hot water and alcohol facilitates penetration of the solvent in the tissue, thereby increasing the extraction yield of the useful substance.
홍삼 혼합 발효 분말의 추출은 다음과 같이 수행하였다. Extraction of red ginseng mixed fermentation powder was performed as follows.
1차 열수추출은 원료 10배의 정제수를 가하여 70℃에서 6시간 환류냉각추출(Reflux extraction)한 후 여과하였고, 2차 주정추출은 잔사에 10배의 주정을 가하여 60℃에서 3시간 환류냉각추출 하고, 여과지로 여과한 다음 감압농축기로 고형분 함량(°Brix)이 15가 되도록 농축하였다.The primary hot water extraction was carried out by reflux extraction at 70 ° C for 6 hours with purified water of 10 times the raw material and then filtered. The secondary alcohol extraction was performed by adding 10 times of alcohol to the residue and refluxing for 3 hours at 60 ° C. , Filtered through a filter paper, and concentrated under reduced pressure to a solids content (Brix) of 15.
제 4단계 (혼합조성물 제조, 포장 및 살균 단계)Step 4 (Mixture composition manufacturing, packaging and sterilization steps)
유용성분의 함량 증대 및 원재료에 대한 기능향상을 위한 방편으로 추출물을 함유하는 홍삼 발효 혼합 조성물의 제조는 홍삼 분말과 발효 혼합 분말(2 단계에서 제조된 것)에 혼합 발효 추출 농축액을 원료중량 대비 10%의 양을 균일하게 분사기로 분사한 다음 40℃에서 건조함으로써 수행한다.The preparation of fermented red ginseng mixed composition containing the extract as a method for increasing the content of the useful ingredient and improving the function of the raw material is carried out by mixing the fermented red ginseng powder and the fermented mixed powder (produced in Step 2) % By weight spraying uniformly into the sprayer and then drying at 40 < 0 > C.
이를 함수율이 5% 이하가 되도록 건조한다. 함수율은 발효산물이 이상 균과 접촉되어 이상발효 내지 부패가 되는 것을 방지하기 위하여 조절해야 하는데, 통상적으로 함수율 6% 이하에서는 미생물의 생육이 불가하기 때문에 건조를 통해 상기 함수율을 맞추는 것이 중요하다. 혼합 분말은 파우치 포장하여 적정온도에서 2차 살균하여 최종 제품을 제조한다.This is dried to a moisture content of 5% or less. The water content should be adjusted in order to prevent the fermentation product from coming into contact with abnormal bacteria to prevent abnormal fermentation or decay. Normally, it is important to adjust the water content by drying because the microorganism can not grow at a water content of less than 6%. The mixed powder is packed in a pouch and then sterilized at an appropriate temperature to produce the final product.
본 발명의 기능성 식품 조성물의 효과를 확인하기 위하여 고환손상 유도제 처리한 흰쥐의 고환과 타 장기에 미치는 영향을 조사하였고, 발기부전을 유도한 흰쥐의 간 해독 작용, 활성산소 소거계 효소활성, 성기능 개선을 조사하였다.To investigate the effect of the functional food composition of the present invention on the testes and other organs of rats treated with testosterone damage inducer, the effect of erythropoietin-induced liver detoxification, active oxygen scavenging enzyme activity, sexual function improvement Respectively.
실험 1. 본 발명의 식품 조성물이 2-Experiment 1. The food composition of the present invention is 2- bromopropane(고환손상 유도제)을bromopropane (testis damage inducer) 처리한 흰쥐의 고환과 타 장기에 대한 영향 및 산화적 손상 정도에 미치는 영향 Effects of testicular and other organs on the degree of oxidative damage in treated rats
1) 실험군 및 식이의 조제1) Preparation of experimental group and diet
실험군은 정상군(NC), 2-브로모프로판(2-bromopropane) 투여 대조군(B), 2-브로모프로판을 투여한 후 홍삼 2% 식이군(BR), 2-bromopropane 투여 및 홍삼 및 혼합조성물 2% 식이군(BRM), 2-bromopropane 투여 및 홍삼 및 발효혼합조성물 2% 식이군(BRFM) 등의 5개 실험군으로 분류하였다. In the experimental group, the control group (B), 2-bromopropane-treated group, red ginseng group (BR), 2-bromopropane group and red ginseng (BRM), 2-bromopropane administration, and 2% dietary group (BRFM) containing red ginseng and fermented mixed composition.
이때 홍삼 추출액, 홍삼 식물 혼합 조성물 추출액 및 홍삼 발효 식물 혼합 조성물 추출액(각 고형분 함량 °Brix 20)은 모두는 절반으로 농축하여 농도를 2배로 높인 것을 시료로 사용하였다. At this time, red ginseng extract, red ginseng plant composition extract solution and red ginseng fermentation plant mixture composition extract (each solid content Brix 20) were used as samples in which the concentration was doubled and the concentration was doubled.
조성물 식이는 표 2와 같은 조건으로 4주간 공급하였다. 기본식이(AIN 76-A diet), 미네랄믹스쳐 및 비타민 믹스쳐는 모두 미국 다카드사(Teklad, USA) 조성표를 기준으로 조제하였다.The composition diet was fed for 4 weeks under the same conditions as in Table 2. The basic diet (AIN 76-A diet), minerals mixer and vitamin mixer were all prepared based on the composition of the United States Daughter Card (Teklad, USA).
표 2에서 AIN 미네랄혼합(g/㎏)은 젖산칼슘 620.0g, 염화나트륨 74.0g, 인삼칼륨(염기성) 220.0g, 황산칼륨 52.0g, 산화마그네슘 23.0g, 탄산제일망간 3.3g, 구연산철 6.0g, 탄산아연 1.0g, 탄산제이구리 0.2g, 요오드산칼륨 0.01g, 아셀렌산나트륨 0.01g, 크로뮴황산칼륨 0.5g의 비율로 혼합된 것이며 최종 조제 중량 1,000 g이다. 또한, AIN 비타민혼합(㎎/㎏)은 티아민-염화수소 600㎎, 리보플라빈 600㎎, 피리독신-염화수소 700㎎, 니코틴산 3,000㎎, D-판토텐산칼슘 1,600㎎, 폴산 200㎎, D-바이오틴 20㎎, 비타민 B12 2.5㎎, 비타민 A 400,00 IU, 비타민 D3 100,000 IU, 비타민 E 7,500 IU, 비타민 K 75㎎으로 최종 조제 중량 1,000 g이다.In Table 2, the AIN mineral mixture (g / kg) contains 620.0 g of calcium lactate, 74.0 g of sodium chloride, 220.0 g of ginseng potassium (basic), 52.0 g of potassium sulfate, 23.0 g of magnesium oxide, 3.3 g of manganese carbonate, 1.0 g of zinc carbonate, 0.2 g of cupric carbonate, 0.01 g of potassium iodate, 0.01 g of sodium selenite, and 0.5 g of potassium chromium sulfate. The final preparation weight is 1,000 g. The AIN vitamin mixture (mg / kg) also contained 600 mg thiamine-hydrogen chloride, 600 mg riboflavin, 700 mg pyridoxine-hydrogen chloride, 3,000 mg nicotinic acid, 1,600 mg calcium D-pantothenate, 200 mg folate, 20 mg D- 2.5 mg, Vitamin A 400.00 IU, Vitamin D3 100,000 IU, Vitamin E 7,500 IU, Vitamin K 75 mg and the final preparation weight is 1,000 g.
2) 실험동물 및 사육방법2) Experimental animals and breeding methods
실험동물은 6주령의 평균체중이 150±10g인 흰쥐(Sprague-Dawly SPF/VAF outbred rats, 오리엔트, 대한민국 성남시)를 1주일간 환경에 적응시킨 후 각 실험군에 7마리씩으로 하여 4주간 사육하였다. Experimental animals were housed in a rats (Sprague-Dawly SPF / VAF outbred rats, Orient, Seongnam, Korea) with an average body weight of 150 ± 10g at 6 weeks of age for 7 weeks in each experimental group.
실험환경에 적응시키기 위해 1 주일간 일반 배합사료(Rat & Mouse 18%, PMI Nutrition International, LLC., USA)로 예비사육 하였다. 기본식이와 물은 자유 공급하였으며, 실험에 사용한 모든 식이는 신선도를 유지하기 위해 1주일에 한번 씩 제조하여 4℃에 냉장보관하면서 실험동물에게 공급하였다. (Rat & Mouse 18%, PMI Nutrition International, LLC, USA) for 1 week to adapt to the experimental environment. All the diets used in the experiment were prepared once a week to maintain freshness and fed to the experimental animals in a refrigerator at 4 ° C.
동물은 1마리씩 스텐레스스틸 케이지에 사육하였으며, 사육 조건은 온도 23±2℃, 습도 60±5%를 유지시켰으며, 명암은 12시간 (06:00~18:00)을 주기로 자동 조절하였다. Animals were kept in a stainless steel cage at a temperature of 23 ± 2 ° C and humidity of 60 ± 5%. The darkness was automatically adjusted to 12 hours (06: 00 ~ 18: 00).
3) 고환 손상유도3) induction of testicular injury
동물의 고환 손상을 유발시키기 위하여 Kim 등(Kim J. C., Shin J. Y., Shin D. H., Kim S. H., Bae C. S., Park S. C., Cha S. W., Kang B. H., Chung M. K., Establishment of short-term screening test for detect testicular toxicity in rats: 2-Bromopropane as an example. Laboratory Animal Research 21: 26-34, 2005)과 Cha 등(Cha S. E., Park S. R., Choi C. S., Yoon S. H., Acute toxicity of 2-bromopropane in rats. J. Korean Soc Hygienic Sciences 2: 38-48, 1996)의 방법에 따라 2-브로모프로판(2-bromopropane, Sigma Chem. Co., MO, USA)과 올리브유를 1:1 (v/v)의 비율로 혼합하여 일정한 시간에 0.2㎖/100g BW(body weight)을 2일에 1회씩 3주간 피하에 주입하였다. 대조군은 동량의 올리브유를 주입하였다.In order to induce testicular damage in animals, Kim et al. (Kim JC, Shin JY, Shin DH, Kim SH, Bae CS, Park SC, Cha SW, Kang BH, Chung MK, Establishment of short-term screening test for detect testicular toxicity in (2) Bromopropane as an example. Laboratory Animal Research 21: 26-34, 2005) and Cha et al. (Cha SE, Park SR, Choi CS, Yoon SH, Acute toxicity of 2-bromopropane in rats, J. Korean Soc Hygienic 2-bromopropane (Sigma Chem. Co., MO, USA) and olive oil were mixed at a ratio of 1: 1 (v / v) 0.2 ml / 100 g BW (body weight) was injected subcutaneously once every 2 days for 3 weeks. The control group was injected with the same amount of olive oil.
4) 고환크기 측정4) Testicle size measurement
고환크기는 micrometer caliper (Mitutoyo, Japan)를 이용하여 1주일에 3회 측정하였다. Testis size was measured three times per week using a micrometer caliper (Mitutoyo, Japan).
5) 체중증가량, 식이 섭취량, 식이효율 및 음용수 섭취량5) Weight gain, dietary intake, diet efficiency and drinking water intake
체중, 식이 및 음용수 섭취량은 매일 일정한 시간에 측정하였다. 식이효율 (Food Efficiency Ratio; FER)은 실험기간 동안의 체중 증가량을 총 식이섭취량으로 나누어 계산하였다.Weight, dietary, and drinking water intake were measured daily at regular intervals. The Food Efficiency Ratio (FER) was calculated by dividing the weight gain during the study period by the total dietary intake.
6) 실험동물의 처치 및 효소원의 조제 6) Treatment of experimental animals and preparation of enzyme source
4주간 사육 후 12시간 절식시키고 식수만 공급받은 동물은 에테르로 마취하여 복부 대동맥으로부터 채혈하였다. 고환조직의 효소원 조제를 목적으로 적출된 좌측 고환 일정량에 3배의 0.25M sucrose 용액을 가하여 마쇄하였다. 마쇄 균질액은 10,000xg에서 30분간 원심분리하여 얻은 포스트미토콘드리알 프렉션(PMF: post-mitochondrial fraction)을 효소활성 측정에 이용하였다. After 4 weeks of feeding, the animals were fasted for 12 hours. Animals fed only with drinking water were anesthetized with ether to collect blood from the abdominal aorta. The testes were sacrificed by the addition of 3 times 0.25 M sucrose solution to the left testis which had been extracted for the purpose of preparing testis tissue. The post-mitochondrial fraction (PMF) obtained by centrifuging the milled homogenate at 10,000 × g for 30 minutes was used for enzyme activity measurement.
7) 간 조직의 글루타치온 (glutathione) 및 과산화 지질의 함량 측정7) Determination of the content of glutathione and lipid peroxidation in liver tissue
간 조직 글루타치온(glutathione: GSH)의 함량은 Ellman의 방법(Ellman GL: Tissue sulfhydryl group. Arch Biochem Biophys 82: 70-77, 1959)에 따라 적출한 동물의 간 조직 균질액에 2-니트로벤조닉산(2-nitrobenzoic acid)를 가해 생성되는 티오페놀(thiophenol)의 측정하였으며 간 조직 g당 환원형 글루타티온 μmol로 나타내었다. 과산화지질(Lipid peroxide, LPO)의 함량은 Satho의 방법(Satho K., Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin. Chim. Acta 90: 37-43 1978.)에 따라 간 조직 균질액에 티오바비투릭산(thiobarbituric acid, TBA) 용액을 가하여 반응시킨 후 부탄올(n-butanol)을 가해 이행되는 티오바비투릭산 반응물질(TBA-reactive substance)의 흡광도를 532 nm에서 측정, 분자흡광계수, ε=1.5×105 M-1·cm- 1를 이용하여 함량을 산출하였으며 간 조직 g당 nmol로 나타내었다.The content of hepatic tissue glutathione (GSH) was determined by adding 2-nitrobenzoic acid (2-nitrobenzoic acid) to the liver tissue homogenate of the animal according to Ellman's method (Ellman GL: Tissue sulfhydryl group. Arch Biochem Biophys 82: 70-77, 2-nitrobenzoic acid was added to determine the amount of thiophenol produced and the reduced glutathione per gram of liver tissue was expressed in μmol. The content of lipid peroxide (LPO) was determined according to the method of Satho (Satho K., Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method, Clin. Chim. Acta 90: 37-43 1978.) The absorbance of a thiobarbituric acid (TBA) solution was measured by measuring the absorbance of a thiobarbituric acid reactive substance (TBA-reactive substance), which was reacted with n-butanol, at 532 nm, coefficient, ε = 1.5 × 10 5 M -1 · cm - was expressed as nmol per g liver tissue using a first content was calculated.
8) 고환 조직의 glutathione S-transferase, xanthine oxidase 활성도 측정8) Measurement of glutathione S-transferase and xanthine oxidase activity in testis tissue
글루타치온 에스 트렌스퍼라제의 활성은 Habig등의 방법(Habig W. H., Pabst M. J., Fleischner G., Gatmaitan F., Aris I. M., Jacoby W. B., The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc. Natl. Acad. Sci. USA 71: 3879-3882, 1974.)에 따라 기질인 1-클로로-2,4-디니트로벤젠 (1-chloro-2,4-dinitroezene, CDNB)과 환원성 글루타치온이 포합하여 생성되는 티오에테르(thioether)를 파장 340nm에서 측정하였으며, 활성도는 분당 단백 1㎎이 생성시킨 티오에테르 량을 nmol로 나타내었다. 잔틴산화환원효소의 활성은 Stirpe F & Della Corte의 방법(Stirpe F., Della Corte E., The regulation of rat liver xanthine oxidase. J. Biol. Chem. 244: 3855-3860, 1969.)에 따라 토탈 타입(total type) 활성은 니코틴산아마이드의 존재 하에서, O 타입(O type) 활성은 니코틴산아마이드를 첨가하지 않은 상태에서 생성되는 요산의 함량을 파장 292nm에서 측정하였으며, 활성도는 분당 단백 1 ㎎이 기질인 잔틴으로부터 생성되는 요산의 량을 nmol로 나타내었다. 단백질 함량은 소의 혈청알부민(bovine serum albumin, BSA)을 표준용액으로 하여 Lowry 법(Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. L., Protein measurement folin phenol reagent. J Biol Chem 193: 265-275, 1951.)으로 측정하였다.The activity of glutathione estransferase was determined by the method of Habig et al. (Habig WH, Pabst MJ, Fleischner G., Gatmaitan F., Aris IM, Jacoby WB, The identity of glutathione S-transferase B with ligandin, 1-chloro-2,4-dinitroezene (CDNB), which is a substrate, and reducing glutathione (CDNB) according to Proc. Natl. Acad. Sci. USA 71: 3879-3882, The thioether produced in this way was measured at a wavelength of 340 nm. The activity was expressed in nmol as the amount of thioether produced by 1 mg protein per minute. The activity of xanthine oxidoreductase was determined according to the method of Stirpe F & Della Corte (Stirpe F., Della Corte E., The regulation of rat liver xanthine oxidase, J. Biol. Chem. 244: 3855-3860, 1969.) The total type activity was measured in the presence of nicotinic acid amide and the content of uric acid produced in the absence of nicotinic acid amide (O type) activity at a wavelength of 292 nm. The activity was measured in the presence of 1 mg / The amount of uric acid produced from xanthine was expressed in nmol. Protein content was determined by the Lowry method (Lowry OH, Rosebrough NJ, Farr AL, Randall RL, Protein measurement folin phenol reagent, J Biol Chem 193: 265-275, 1951) using bovine serum albumin (BSA) ).
실험 2. 본 발명의 식품 조성물이 에탄올에 의해 발기부전을 유도한 흰쥐의 간 해독 작용, 활성산소(Reactive Oxygen Species, ROS) 소거계 효소활성 및 성기능 개선에 미치는 영향
1) 실험동물 및 식이의 조제1) Preparation of experimental animals and diets
실험식이의 조성은 표 3과 같다. The composition of the experimental diet is shown in Table 3.
실험동물은 6주령의 평균체중이 150±10g인 흰쥐(Sprague-Dawly SPF/VAF outbred rats, 오리엔트, 대한민국 성남시)를 1주일간 환경에 적응시킨 후 정상군(NC), 에탄올대조군(EN), 홍삼 5% 식이군(ER), 홍삼 및 혼합조성물 5% 식이군(ERM), 홍삼 및 발효혼합조성물 5% 식이군(ERFM) 등의 5개 실험군으로 나누어(총 5군) 각각 7마리씩으로 하여 4주간 사육하였다. Experimental animals were randomly divided into two groups: normal (NC), ethanol control (EN), red ginseng (EN), and ginseng (ER), red ginseng and
이때 홍삼 추출액, 홍삼 식물 혼합 조성물 추출액 및 홍삼 발효 식물 혼합 조성물 추출액(각 고형분 함량 oBrix 20) 모두는 절반으로 농축하여 농도를 2배로 높인 것을 시료로 사용하였다. At this time, all the extracts of red ginseng extract, red ginseng plant composition extract and red ginseng fermentation plant mixture composition (each solid content o Brix 20) were concentrated to half and the concentration was doubled.
대조군과 실험군은 알코올 중독에 의한 발기부전을 유도하기 위하여 이틀 간격으로 50% 에탄올 용액을 체중 kg당 0.2g씩 경구투여 하였다. 4주간 사육한 실험동물은 공복 상태에서 일일 1회, 2일간 50% 에탄올 용액을 체중 kg당 5g씩 경구투여하였으며, 마지막 투여 후 12시간이 경과한 다음 처치하였다. In the control and experimental groups, 50% ethanol solution was orally administered at 0.2g / kg body weight every two days in order to induce impotence caused by alcohol poisoning. For 4 weeks, 50% ethanol solution was orally administered in fasted state once a day and 5 g / kg body weight for 2 days, and then treated 12 hours after the last administration.
사육장은 스테인레스 스틸 케이지를 사용하고, 온도 및 습도는 23±2℃, 60±5%로 조정하고, 명암주기는 12시간 간격으로 설정하고, 물과 사료의 섭취는 자유 섭취시켰다.The temperature and humidity were adjusted to 23 ± 2 ° C and 60 ± 5%, and the dark and light cycles were set at 12-hour intervals, and water and feed intake were freely consumed.
표 3에서 고형사료는 5L79 diet of PMI Nutrition(LLC, PO Box 19798, Brentwood MO 63144, USA)으로서 성분함량은 조단백 18 중량%, 조지방 5 중량%, 조섬유 5 중량%, 회분 8 중량%이다.As shown in Table 3, the solid feed is 18 wt% of crude protein, 5 wt% of crude fat, 5 wt% of crude fiber, and 8 wt% of ash in a 5L79 diet of PMI nutrition (LLC, PO Box 19798, Brentwood MO 63144, USA).
2) 체중, 식이섭취량 및 음용수 섭취량2) Weight, Dietary Intake and Drinking Water Intake
체중, 식이 및 음용수 섭취량은 전 실험 기간을 통하여 매일 일정한 시간에 측정하였다. 식이효율은 일일 증체량을 일일 식이 섭취량으로 나눈 값으로 하였다. Weight, dietary, and drinking water intake were measured at regular intervals throughout the day. Dietary efficiency was calculated by dividing daily gain by daily dietary intake.
3) 분석시료의 채취3) Sampling of analytical samples
실험식이로 4주간 사육한 흰쥐를 물은 자유롭게 먹게 하고, 12시간 동안 절식시킨 후 에테르 마취 하에서 복부 대동맥으로부터 채혈한 다음, 빙냉의 생리식염수로 간을 관류하고 장기를 적출 한 후 습기를 제거하여 무게를 측정하였다. The rats fed the diet for 4 weeks were allowed to drink water freely. After fasting for 12 hours, blood was drawn from the abdominal aorta under ether anesthesia. The liver was perfused with ice-cold physiological saline and the organs were removed. Were measured.
음경해면체는 동물의 하복부를 절개하여 적출하였으며, 적출한 음경해면체를 생리식염수로 깨끗하게 세척한 후, 남아 있는 이물질 및 혈액을 여지로 제거하였다. 음경해면체 조직 1g 당 4배량의 0.1 M 포타슘포스페이트버퍼(potassium phosphate buffer, pH 7.4) 용액을 가하여 균질기로 마쇄하여 균질액을 획득한 다음 10,000xg의 조건에서 원심분리한 상징액을 효소활성 실험에 사용하였다.The corpus cavernosum was excised from the lower abdomen of the animal, and the excised penile corpus cavernosum was cleaned with physiological saline, and the remaining foreign matter and blood were removed with a filter paper. Four times the amount of 0.1 M potassium phosphate buffer (pH 7.4) solution per 1 g of corpus cavernosum tissue was added, and homogenized with a homogenizer to obtain a homogenate. The supernatant was centrifuged at 10,000 × g for enzyme activity test .
채취한 혈액은 실온에서 응고시킨 다음 4℃, 2,500 rpm으로 20분간 원심분리 하여 혈청을 분리한 후 -70℃에 두면서 분석용 시료로 사용하였다. The collected blood was coagulated at room temperature, centrifuged at 4 ° C and 2,500 rpm for 20 minutes, and the serum was separated and used as an analytical sample at -70 ° C.
4) 혈청 알라닌 아미노전이효소의 활성 측정4) Measurement of activity of serum alanine aminotransferase
혈청 알라닌 아미노전이효소(alanine aminotransferase, ALT) 활성도는 키트 시약(아산제약, 대한민국)을 사용하여 측정하였으며 활성도는 혈청 1㎖당 칼멘 유닛(Karmen unit)으로 나타내었다(Karmen A., A note on the spectrophotometric assay of glutamic oxaloacetic transaminase in human blood serum. J. Clin. Invest. 34: 131-133, 1955.).The activity of alanine aminotransferase (ALT) was measured using a kit reagent (ASAN PHARMACEUTICAL, Korea) and the activity was expressed as Karmen unit per 1 mL of serum (Karmen A., A note on the spectrophotometric assay of glutamic oxaloacetic transaminase in human blood serum. J. Clin. Invest. 34: 131-133, 1955.).
5) 간 조직의 글루타치온, 과산화지질 및 지질 함량5) Glutathione, lipid peroxide and lipid content of liver tissue
간 조직 글루타치온(glutathione: GSH)의 함량은 Ellman의 방법(Ellman G. L., Tissue sulfhydryl group. Arch Biochem Biophys 82: 70-77, 1959.)에 따라 적출한 동물의 간 조직 균질액에 2-니트로벤조닉산(2-nitrobenzoic acid)를 가해 생성되는 티오페놀(thiophenol)의 측정하였으며, 간 조직 g당 환원형 글루타티온 μmol로 나타내었다. 과산화지질(Lipid peroxide, LPO)의 함량은 Satho의 방법(Satho K., Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 90(1): 37-43, 1978.)에 따라 간 조직 균질액에 티오바비투릭산(thiobarbituric acid, TBA) 용액을 가하여 반응시킨 후 부탄올(n-butanol)을 가해 이행되는 티오바비투릭산 반응물질(TBA-reactive substance)의 흡광도를 532 nm에서 측정, 분자흡광계수, ε=1.5×105 M-1·cm- 1를 이용하여 함량을 산출하였으며 간 조직 g당 nmol로 나타내었다. The content of hepatic tissue glutathione (GSH) was determined by adding 2-nitrobenzoic acid to the hepatic tissue homogenate of the animal extracted according to Ellman's method (Ellman GL, Tissue sulfhydryl group. Arch Biochem Biophys 82: 70-77, 1959.) (2-nitrobenzoic acid) was added to determine the amount of thiophenol produced, and it was expressed as μmol of reduced glutathione per g of liver tissue. The content of lipid peroxide (LPO) was determined according to the method of Satho (Satho K., Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method, Clin Chim Acta 90 (1): 37-43, 1978.) The absorbance of a thiobarbituric acid (TBA) solution was added to the tissue homogenate and reacted with n-butanol to measure the absorbance of the thiobarbituric acid reactant (TBA-reactive substance) at 532 nm. molecular extinction coefficient, ε = 1.5 × 10 5 M -1 · cm - was expressed as nmol per g liver tissue using a first content was calculated.
간 조직의 지질은 Folch의 방법(Folch J., Lees M., Sloane G. H., A simple method for isolation and purification of total lipids from animal tissue. J. Biol. Chem. 226: 497-509, 1957.)으로 추출하여 지질측정용 시료로 사용하였으며 총지질 함량은 Frings와 Dunn의 방법(Frings C. S., Dumm R. T., A colorimetric method for determination of total serum lipid based on the sulfophosphovanillin reaction. Am. J. Clin. Path. 53: 89-91, 1970.)으로 측정하였다.The lipid of the liver tissue was analyzed by Folch's method (Folch J., Lees M., Sloane GH, A simple method for isolation and purification of total lipids from animal tissue, J. Biol. Chem. 226: 497-509, 1957) The total lipid content was determined by the method of Frings and Dunn (Frings CS, Dumm RT, A colorimetric method for determination of total serum lipid based on sulfophosphovanillin reaction. Am. J. Clin. Path. 53: 89-91, 1970.).
6) 음경해면체 조직의 효소 활성 측정6) Enzyme activity measurement of corpus cavernosal tissue
니트릭옥시드 신타아제(nitric oxide synthase), 슈퍼옥시드 디스무타아제(superoxide dismutase: SOD), 글루타치온 퍼옥시다아제(glutathione peroxidase: GPX), 카탈라아제(catalase: CAT), 글루타치온 에스-트렌스퍼라제(glutathione S-transferase: GST)활성 측청용 효소원은 적출한 동물의 간 조직 일정량에 4배량의 빙냉의 0.25 M 설탕 용액을 가하여 균질화한 다음 10,000×g에서 20분간 원심분리하여 나온 상징액(postmitochondrial fraction, PMF) 및 미토콘드리아 분획을 사용하였다. 니트릭옥시드 신타아제 활성은 니코틴아미드 아데닌 디뉴클레오티드 인산(NADPH) 디아포라아제(diaphorase) 활성도 측정법을 이용하였다. 효소의 활성도는 파장 585 nm에서 측정한 흡광도 수치에 사용한 단백질의 함량을 나눈 값으로 산정하였다.A nitrite oxidase synthase, superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase (CAT), glutathione S-transferase S-transferase: GST) An enzyme source for active surveillance was prepared by homogenizing an ice-cold 0.25 M sugar solution with a 4-fold amount of the liver tissue of the extracted animal and then centrifuging at 10,000 xg for 20 minutes to obtain a supernatant (postmitochondrial fraction, PMF ) And mitochondrial fractions were used. Nitric oxide synthase activity was measured using the nicotinamide adenine dinucleotide phosphate (NADPH) diaphorase activity assay. The activity of the enzyme was calculated by dividing the amount of protein used in the absorbance value measured at a wavelength of 585 nm.
슈퍼옥시드 디스뮤타아제 활성은 헤마토자일렌(hematoxylin) 자동산화의 억제 정도를 측정하는 Martin등의 방법(Martin J. P., Dailey J. M., Sugarmanand E., Negative and positive assays of superoxide dismutase based on hematoxylin autoxidation. Arch. Biochem. Biophys. 255: 329-336, 1987.)에 따라 파장 560nm에서 측정하였으며, 활성도는 효소 부재 하에서 헤마토자일렌의 자동산화를 50% 억제하는 단백의 함량(Unit)으로 나타내었다. 글루타치온 퍼옥시다아제의 활성은 Pagila & Valentine의 방법(Pagila E. D. and Valentine W. N., Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 7: 158-169)에 준해 반응시키는 동안 기질인 과산화수소를 환원시키는데 소모되는 환원성 글루타치온(reduced glutathione)을 글루타치온 환원효소(glutathione reductase)가 글루타치온로 재환원시키는데 이용하는 니코틴아미드 아데닌 디뉴클레오티드 인산(NADPH)의 함량을 파장 340nm에서 측정하였으며, 활성도는 분당 단백 1㎎이 소모한 니코틴아미드 아데닌 디뉴클레오티드 인산의 량을 nmol로 나타내었다. 카탈라아제의 활성은 Claibome의 방법(Claibome A., Catalase activity in "CRC Handbook of Methods for Oxygen Radical Research; ed. RA Greenwald. CRC Press, Florida. pp. 283-284, 1986.)에 따라 반응시키는 동안 분해되는 과산화수소의 함량을 파장 240nm에서 측정하였으며, 활성도는 분당 단백 1㎎이 분해시킨 과산화수소의 량을 nmol로 나타내었다. 글루타치온 에스 트렌스퍼라제의 활성은 Habig 등의 방법(Habig W. H., Pabst M. J., Fleischner G., Gatmaitan F., Aris I. M., Jacoby W. B., The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc Natl Acad Sci USA 71: 3879-3882 (1974)에 따라 기질인 1-클로로-2,4-디니트로벤젠(1-chloro-2,4-dinitroezene, CDNB)과 환원성 글루타치온이 포합하여 생성되는 티오에테르(thioether)를 파장 340nm에서 측정하였으며, 활성도는 분당 단백 1㎎이 생성시킨 티오에테르 량을 nmol로 나타내었다. The superoxide dismutase activity is determined by the method of Martin et al. (Martin, J., Dailey JM, Sugarman, E., Negative and positive assays of hematoxylin autoxidation on the hematoxylin autoxidation assay. Arch. Biochem. Biophys. 255: 329-336, 1987.), and the activity was expressed as the protein content of 50% inhibition of autooxidation of hematoxylin in the absence of enzyme. The activity of glutathione peroxidase is determined by the method described by Pagila & Valentine WN, Studies on the Quantitative and Qualitative Characterization of Erythrocyte Glutathione Peroxidase, J. Lab. Clin. Med. 7: 158-169, The content of nicotinamide adenine dinucleotide phosphate (NADPH), which is used for reducing glutathione reductase to glutathione reductase, was measured at a wavelength of 340 nm. Reduced glutathione, which is consumed for reducing hydrogen peroxide, The amount of nicotinamide adenine dinucleotide phosphate consumed by 1 mg was expressed in nmol. Catalase activity is determined by the method described in Claibome A., Catalase activity in CRC Handbook of Methods for Oxygen Radical Research, ed. RA Greenwald, CRC Press, Florida, pp. 283-284, The activity of glutathione estransferase was determined by the method of Habig et al. (Habig WH, Pabst MJ, Fleischner G, et al. According to Proc Natl Acad Sci USA 71: 3879-3882 (1974), the substrate 1-chloro < RTI ID = 0.0 > Thioether produced by the incorporation of 1-chloro-2,4-dinitroezene (CDNB) and reducing glutathione was measured at a wavelength of 340 nm. The amount of thioether is expressed in nmol I got it.
7) 단백질 함량 측정7) Measurement of protein content
간 조직의 단백질 함량은 소의 혈청알부민(bovine serum albumin, BSA)을 표준용액으로 하여 Lowry 법(Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. L., Protein measurement folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.)으로 측정하였다. The protein content of liver tissue was determined by the Lowry method (Lowry OH, Rosebrough NJ, Farr AL, Randall RL, Protein measurement folin phenol reagent, J. Biol. Chem., 193 : 265-275, 1951).
실험 1에 대한 결과 및 평가Results and Evaluation for Experiment 1
1) 체중 증체량, 식이 섭취량 및 식이 효율1) Weight gain, dietary intake and diet efficiency
4주간 사육한 흰쥐의 체중, 증체량, 식이 섭취량 및 식이 효율의 결과는 표 4에 제시하였다. The results of weight, weight gain, dietary intake and diet efficiency of the rats raised for 4 weeks are shown in Table 4.
증체량은 무처리 NC군에 비해 2-브로모프로판에 노출된 B군이 22.75% 감소되었다. 이러한 감소현상은 홍삼(BR), 홍삼 혼합 조성물(BRM), 홍삼 발효 혼합 조성물(BRFM) 식이에 의하여 회복되지 않았으나 홍삼 발효 혼합 조성물의 식이가 타 식이에 체중증가를 유발하였다. Body weight was reduced by 22.75% in group B exposed to 2-bromopropane compared to untreated NC group. This decrease was not restored by red ginseng (BR), red ginseng mixed composition (BRM) and red ginseng fermented mixed composition (BRFM) diets, but diet of red ginseng fermented mixed composition caused weight gain in rats.
식이 섭취량은 B군이 N군에 비하여 다소 감소하였으며, 감소율이 홍삼 또는 홍삼 발효 혼합 조성물 식이로 인하여 회복되는 경향을 보였으나 큰 차이는 없었다. 실험군 간의 식이효율은 B군이 N군에 비하여 20.00% 정도가 감소하였으며, 홍삼, 홍삼 혼합 조성물, 홍삼 발효 혼합 조성물 식이에 의하여 그 감소율이 회복되지 않았다.Dietary intake was slightly decreased in group B than in group N, and the reduction rate tended to be recovered by the red ginseng or red ginseng fermented mixed composition diet, but there was no significant difference. The dietary efficiency of the experimental group was decreased by 20.00% compared to that of group B, and the reduction rate of red ginseng, red ginseng mixed composition and red ginseng fermented mixture composition was not recovered.
본 실험결과에서 2-브로모프로판 투여 동물의 체중 감소현상은 종래의 연구보고서(Heo J. D., Kim C. Y., Ziang C. Z., Suh J. E., Chung M. K., Kim M. K., Shin D. H., Kim J. C., Evaluation of material toxicity in mice exposed to the environment pollutant 2-bromopropane during pregnancy. Kor. J. Lab. Anim. Sci. 20: 89-95, 2004.) 결과와 일치하였다. The results of this experiment showed that the weight loss of 2-bromopropane-treated animals was significantly lower than that of 2-bromopropane-treated animals (Heo JD, Kim CY, Ziang CZ, Suh JE, Chung MK, Kim MK, Shin DH, The results were consistent with the results of the pollutant 2-bromopropane during pregnancy, Kor J. Lab. Anim. Sci., 20: 89-95, 2004.).
한편 홍삼 발효 혼합 조성물 식이에서 다소의 체중증가를 초래한 것은 식이섭취량 증가와 식이효율성 향상과 관련이 있는 것으로 추정된다. 또한, 홍삼 혼합 조성물 식이에 비해 홍삼 발효 혼합 조성물 식이에서 2-브로모프로판과 같은 화학물질에 노출된 동물의 체중이 미약하나마 다소 회복되는 경향을 보이는 것은 발효에 의한 생리활성의 증진과 더불어 홍삼유효성분이 가지는 해독효과(Lee Y. E., Byun S. K., Shin S. H., Jang J. Y., Choi B. I., Park D. S., Jeon J. H., Lim S. H., Hwang S. Y., Kim Y. B., Effect of red ginseng extract on cyclophosphamide teratogenicity in rats. Lab. Anim. Res. 21: 255-261, 2005) 가 복합적으로 작용한 결과인 것으로 판단된다.On the other hand, it was suggested that some weight gain in the red ginseng fermented mixed composition diet was related to the increase of the dietary intake and the improvement of the dietary efficiency. In addition, the body weight of animals exposed to chemical substances such as 2-bromopropane in the red ginseng fermented mixed composition diets compared to that of the red ginseng mixed composition diet tended to recover slightly, but the improvement of the physiological activity by fermentation, (Lee YE, Byun SK, Shin SH, Jang JY, Choi BI, Park DS, Jeon JH, Lim SH, Hwang SY, Kim YB, Effect of red ginseng extract on cyclophosphamide teratogenicity in rats. Res. 21: 255-261, 2005).
(g/week)Weight gain
(g / week)
(g/week)Dietary intake
(g / week)
(FER)Dietary efficiency
(FER)
표 4에서 식이효율은 “총체중증가량/총식이섭취량”에 의해 계산했으며, 모든 데이터는 실험동물 7마리의 “평균값 ± 표준편차”로 나타내었다.In Table 4, the dietary efficiency was calculated by "total weight gain / total dietary intake" and all data were expressed as "mean ± standard deviation" of 7 animals.
2) 고환의 크기 변화2) Change in testicle size
4주간 사육한 흰쥐의 성 기능 증진효과를 검증하기 위하여 2-브로모프로판에 노출된 흰쥐의 고환 크기를 측정한 결과는 표 5에 제시하였다. The testis size of the rats exposed to 2-bromopropane was measured in order to examine the effect of sex enhancement in rats raised for 4 weeks.
동물의 고환은 NC군이 7.34%, B군이 0.12% 정도 증가하였으며, 홍삼(BR), 홍삼 혼합 조성물(BRM), 홍삼 발효 혼합 조성물(BRFM) 식이군에서 각각 9.99%, 11.11%, 11.99% 정도의 증가를 보였다. 2-브로모프로판 처리군인 B군은 성장에 따른 고환 발달이 이루어지지 않았다. 이러한 결과는 고환손상 유도제인 2-브로모프로판의 고환조직세포의 손상 및 이에 따른 고환위축에 의한 것으로 추정된다. 그러나 본 실험의 4주 후에 홍삼혼합조성물 및 홍삼발효혼합조성물식이는 홍삼 단독식이에 비하여 2-브로모프로판 노출군의 고환 크기를 다소 회복시켰다. 복합식이의 주된 성분인 홍삼이외의 발효혼합조성물의 생리활성성분이 2-브로모프로판 독성으로 인한 고환조직세포의 손상을 최소화하여 생식기 기능을 최대한 보호하는 것으로 사료된다.The testes of animals were increased by 7.34% in the NC group and 0.12% in group B, and 9.99%, 11.11%, and 11.99% in the red ginseng (BRM) and red ginseng fermented mixed composition (BRFM) . B group, which was treated with 2-bromopropane, did not develop testicular development after growth. These results suggest that 2 - bromopropane induces testicular tissue damage and testicular atrophy. However, after 4 weeks of the experiment, the red ginseng mixed composition and red ginseng fermented mixed composition diet slightly recovered the testis size of the 2 - bromopropane - exposed group compared to the red ginseng alone diet. It is considered that the physiologically active component of the fermented mixed composition other than red ginseng, which is the main component of the complex type, protects the reproductive function as much as possible by minimizing the damage of testicular tissue cells due to 2 - bromopropane toxicity.
표 5에서 데이터는 실험동물 7마리의 “평균값 ± 표준편차”로 나타내었다.In Table 5, data were expressed as "mean ± standard deviation" of 7 animals.
3) 장기 중량3) Long weight
4주간 사육한 흰쥐의 장기 중량은 체중에 대한 퍼센트 비율로 환산하여 표 6에 제시하였다. The long-term weight of the rats raised for 4 weeks is shown in Table 6 as a percentage of body weight.
B군의 고환 중량은 N군에 비하여 26.44% 감소하였으며, 홍삼(BR), 홍삼혼합조성물(BRM), 홍삼발효혼합조성물(BRFM) 식이군에서 다소 증가하는 경향을 보였다. N군에 비하여 B군의 간 중량은 7.14% 감소한 반면 홍삼발효혼합조성물 식이군 BRFM군 에서는 무처리군에 근접할 정도의 간 중량을 회복하였다.Testicular weight of group B decreased by 26.44% compared with that of group N and showed a tendency to increase slightly in the groups of red ginseng (BR), red ginseng mixed composition (BRM) and red ginseng fermented mixed composition (BRFM). The liver weight of group B decreased by 7.14% compared with that of group N, but the liver weight of the BRFM group in the red ginseng fermented mixed composition group was recovered to a level close to that of the untreated group.
고환손상 유도제인 2-브로모프로판을 투여한 동물실험(Kim J. C., Shin J. Y., Shin D. H., Kim S. H., Bae C. S., Park S. C., Cha S. W., Kang B. H., Chung M. K.. Establishment of short-term screening test for detect testicular toxicity in rats: 2-Bromopropane as an example. Laboratory Animal Research 21: 26-34, 2005.)에서 정상동물에 비하여 고환과 간 중량이 감소하였데, 본 실험에서도 유사한 결과를 얻었다. Animal experiments with 2-bromopropane as a testicular damage inducer (Kim JC, Shin JY, Shin DH, Kim SH, Bae CS, Park SC, Cha SW, Kang BH, Chung MK. Establishment of short-term screening test test testicular toxicity in rats: 2-Bromopropane as an example. Laboratory Animal Research 21: 26-34, 2005.), testicular and liver weights were decreased compared to normal animals.
실험 식이는 2-브로모프로판에 의해 감소된 고환과 간 중량을 다소 회복시켰으며, 특히 간 기능 회복에 대한 홍삼 발효 혼합 식이의 효능이 관찰되었다. Experimental diet slightly restored testis and liver weight reduced by 2 - bromopropane, especially the effect of red ginseng fermented mixed diet on liver function recovery was observed.
본 결과를 통하여 홍삼 혼합 조성물(BRM)에 비해 발효공정을 가한 홍삼 발효 혼합 조성물(BRFM) 복합식이가 2-브로모프로판에 의해 손상된 장기조직 중 특히 간 세포의 회복에 특이성을 가지는 것으로 사료되며, 손상된 고환기능의 복구에도 잠재적 효능이 있는 것으로 관찰되었다. 홍삼 발효 혼합물의 경우 해독 효능과 홍삼의 생리활성이 복합적으로 작용하여 손상된 특정 장기세포를 회복하는 것으로 추정된다.These results suggest that the red ginseng fermented mixed composition (BRFM) complex, which has a fermentation process compared to the red ginseng mixed composition (BRM), has specificity for the recovery of liver cells, especially in organ tissues damaged by 2 - bromopropane, Potential efficacy has also been observed for repair of damaged testicular function. In the case of fermented red ginseng mixture, it is presumed that the detoxifying effect and the physiological activity of red ginseng are combined to recover the damaged organs.
표 6에서 모든 값은 체중에 대한 퍼센트 비율이며, 데이터는 실험동물 7마리의 “평균값 ± 표준편차”로 나타내었다.In Table 6, all values are percentages by weight and the data are expressed as the "mean value ± standard deviation" of 7 animals.
4) 간 조직의 4) 글루타치온과Glutathione and 과산화지질 농도 및 고환조직의 Peroxide lipid concentration and testicular tissue 잔틴산화와Xanthine oxidation 글루타치온Glutathione 에스s -- 트렌스퍼라제TRANSFERASE 활성 activation
4주간 사육한 후 간 조직의 글루타치온(glutathione, GSH)과 과산화지질(lipid peroxide, LPO) 농도 및 고환조직의 잔틴산화(xanthine oxidase, XO)와 글루타치온 에스-트렌스퍼라제(glutathione S-transferase, GST) 활성을 표 7에 제시하였다.After 4 weeks of incubation, glutathione (GSH), lipid peroxide (LPO) and xanthine oxidase (XO) and glutathione S-transferase (GST ) Activity is shown in Table 7.
글루타치온 농도는 2-브로모프로판을 투여한 군에서 감소하는 경향을 나타낸 반면, 홍삼 발효 혼합 조성물(BRFM)군에서 증가하였다. 과산화 지질 농도는 B군이 N군에 비해 유의적인 증가 추세를 나타내었으며, 홍삼 발효 혼합 조성물 군의 경우 B군에 비해 13.85% 감소하였다. 잔틴산화효소 활성에서는 2-브로모프로판을 투여한 군에서 증가하는 경향을 나타내었으나 홍삼 발효 혼합 조성물 식이군에서 감소되는 결과를 보였다. 글루타치온 에스-트렌스퍼라제 활성은 2-브로모프로판을 투여한 군에서 증가하는 경향을 나타내었는데, 특히 BRM군과 BRFM군이 정상군에 비해 각각 14.86% 및 28.39% 증가하였다.The glutathione concentration tended to decrease in the group administered with 2-bromopropane, while it was increased in the red fermented mixed composition (BRFM) group. The lipid peroxidation concentration of group B showed a significant increase compared with that of group N, and that of red ginseng fermented mixed composition group was 13.85% lower than that of group B. The activity of xanthine oxidase was increased in 2 - bromopropane - treated group but decreased in red ginseng fermented mixed composition group. Glutathione S - transferase activity increased in the 2 - bromopropane - treated group, especially in the BRM and BRFM groups, by 14.86% and 28.39%, respectively.
본 실험에서 2-브로모프로판에 유도된 산화적 손상은 B군의 간조직 글루타치온 농도의 감소를 초래하였으며, 실험식이 중 홍삼 발효 혼합 조성물(BRFM) 식이에 의해 글루타치온 생성을 다소 회복하였다. 생체의 중요한 항산화제로 알려진 글루타치온은 무독화작용을 통하여 2-브로모프로판에 의한 간조직의 산화적 손상이 일부 회복될 것으로 추정된다(Lin T., Yang M. S.. Benzo〔a〕pyrene-induced elevation of GSH level protects against oxidative stress and enhances xenobiotic detoxification in human HepG2 cells. Toxicol. 235: 1-10, 2007.). In this experiment, the oxidative damage induced by 2-bromopropane resulted in a decrease in liver tissue glutathione concentration in group B, and the recovery of glutathione production was somewhat restored by the fermented red ginseng fermentation (BRFM) diet. Glutathione, an important antioxidant in the body, is thought to be partially recovered from oxidative damage of hepatic tissue by 2-bromopropane through the detoxification (Lin T., Yang MS, et al. GSH level protects against oxidative stress and enhances xenobiotic detoxification in human HepG2 cells. Toxicol. 235: 1-10, 2007.).
B군에서 2-브로모프로판 투여는 과산화지질의 현저한 증가가 초래하여 간조직에 산화적 손상이 발생하였음을 증명한다. 생체조직의 산화적 손상에 대한 생물지표로 알려진 과산화지질은 글루타치온 농도가 감소할 때 증가하는 것으로 알려져 있으며(Casini A. F., Pompella A., Comporti M., Glutathione depletion, lipid peroxidation, and liver necrosis following bromobenzene and iodobenzene intoxication. Toxicol Pathol 12: 295-299, 1984.), 본 실험에서도 유사한 결과를 얻었다. Administration of 2-bromopropane in group B provoked a significant increase in lipid peroxidation resulting in oxidative damage to liver tissue. The lipid peroxidation, known as a biomarker of oxidative damage to living tissue, is known to increase with decreasing glutathione concentrations (Casini AF, Pompella A., Comporti M., Glutathione depletion, lipid peroxidation, and liver necrosis following bromobenzene and iodobenzene intoxication. Toxicol Pathol 12: 295-299, 1984). Similar results were obtained in this experiment.
본 실험에서 고환조직의 글루타치온 에스-트렌스퍼라제 활성이 N군에 비해 B군에서 증가함으로써 2-브로모프로판와 같은 유독성분을 무독화시키는 것으로 사료된다. 이와 같은 결과는 산화적 스트레스에 의한 생체 조직의 손상이 글루타치온 에스-트렌스퍼라제를 포함한 항산화효소의 생성을 유도한다는 보고와 일치한다(Yang Y., Yang Y., Trent M. B., He N., Lick S. D., Zimniak P., Awasthi Y. C., Boor P. J., Glutathione-S-transferase A4-4modulates oxidative stress in endothelium: possible role in human atherosclerosis. Atherosclerosis 173: 211-21, 2004). In this experiment, glutathione S - transferase activity of testis tissue is increased in group B compared with that of group N, and it is considered that toxic components such as 2 - bromopropane are detoxified. These results are consistent with the report that injury of the biotissue due to oxidative stress induces the production of antioxidant enzymes including glutathione S-transferase (Yang Y., Yang Y., Trent MB, He N., Lick SD, Zimniak P., Awasthi YC, Boor PJ, Glutathione-S-transferase A4-4modulates oxidative stress in endothelium: possible role in human atherosclerosis. Atherosclerosis 173: 211-21, 2004).
따라서 홍삼 발효 혼합 식이군(BRFM)이 간조직 및 고환조직에서의 글루타치온 에스-트렌스퍼라제 활성을 강화함으로써 2-브로모프로판에 노출된 조직의 산화적 손상을 경감시키는 것으로 판단된다.Therefore, it is considered that the group of fermented red ginseng (BRFM) reduces the oxidative damage of the tissue exposed to 2-bromopropane by enhancing glutathione S-transferase activity in liver tissue and testicular tissue.
(μmole/g)
Glutathione
(μmole / g)
(μmole/g)
Lipid peroxide
(μmole / g)
(uric acid nmole/
mg-protein)Xanthine oxidation
(uric acid nmole /
mg-protein)
에스트렌스퍼라제
(thioether nmole/
mg-protein/min)Glutathione -
Estransferase
(thioether nmole /
mg-protein / min)
표 7에서 데이터는 실험동물 7마리의 “평균값 ± 표준편차”로 나타내었다.In Table 7, data were expressed as "mean ± standard deviation" of 7 animals.
실험 2에 대한 결과 및 평가Results and Evaluation for
1) 체중, 식이섭취량 및 음용수 섭취량1) Weight, Dietary Intake and Drinking Water Intake
4주간 실험식이로 성장시키는 동안 만성적 에탄올 투여에 의해 발기부전을 유도한 흰쥐의 식이섭취량, 음용수섭취량, 체중증가량 및 식이효율을 관찰한 결과는 표 8에 제시하였다. The results of observing dietary intake, drinking water intake, body weight gain and dietary efficiency of rats induced by erectile dysfunction by chronic ethanol administration during the 4 weeks experimental diet are shown in Table 8.
체중과 초기체중의 차이로부터 산출한 1일 평균 체중증가량은 정상군이 5.37 g인데 비하여 에탄올 대조군의 경우 3.38 g으로 37.06%가 감소하였다. 반면, 홍삼(BR), 홍삼혼합조성물(BRM), 홍삼발효혼합조성물(BRFM) 식이군의 경우 에탄올 대조군(EN)에 비해 각각 22.19%, 26.63%, 30.18% 상승하였으며, 특히 홍삼발효혼합조성물이 식이효율의 상승과 더불어 만성적 알코올 대사에 의한 체중감소를 회복시키는 것으로 관찰되었다. The daily average weight gain from the differences in body weight and initial body weight was 5.37 g in the normal group, whereas in the ethanol control group it was decreased to 37.0% in the 3.38 g group. On the other hand, in the group of red ginseng (BR), red ginseng mixed composition (BRM) and red ginseng fermented mixed composition (BRFM) group, 22.19%, 26.63% and 30.18% Along with the increase in dietary efficiency, it was observed to restore weight loss due to chronic alcohol metabolism.
(g/일)Dietary intake
(g / day)
(g/일)Drinking water intake
(g / day)
(g/일)Weight gain
(g / day)
표 8에서 식이효율은 “일일 증체량/일일 식이 섭취량”에 의해 계산하였으며, 데이터는 실험동물 7마리의 “평균값 ± 표준편차”로 나타내었다. In Table 8, the dietary efficiency was calculated by "daily gain / daily dietary intake" and the data were expressed as "mean ± standard deviation" of 7 animals.
2) 혈청 알라닌 아미노전이효소 (ALT) 및 아스파르테이트아미노 전이효소(AST) 활성2) Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity
4주간 실험식이로 성장시키는 동안 만성적 에탄올 투여에 의해 발기부전을 유도한 흰쥐의 혈청 알라닌 아미노전이효소(alanine aminotransferase: ALT)와 아스파르테이트 아미노 전이효소(aspartate aminotransferase: AST) 활성변동은 도 2에 제시하였다. The changes in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity in rats induced by erythropoietin induced by chronic ethanol administration during the 4 weeks experimental diet were shown in FIG. 2 Respectively.
에탄올만 급성적으로 처치한 에탄올 대조군은 정상군에 비해 유의하게 증가하였으나, 각종 시료 추출물을 투여한 모든 실험군에서는 알라닌 아미노전이효소의 활성이 현저하게 낮았으며, 특히 홍삼 발효 혼합 조성물 식이군(BRFM)의 경우 정상군의 범주에 유사한 수치를 나타내었다. 혈청 알라닌 아미노전이효소와 아스파르테이트 아미노 전이효소의 활성은 간 조직 손상에 의해 증가하는 것으로 잘 알려져 있어 임상에서 간 조직 손상의 지표로 널리 이용되고 있다(Reitman S. and Frankel S., A colorimetric method for the determination of serum glutamic oxaloacetic pyruvic transaminase. Am. J. Clin. Pathol. 28: 58-63, 1957.). The activity of alanine aminotransferase was significantly lower in all the experimental groups treated with ethanol extract than in the normal group, but the activity of alanine aminotransferase was remarkably lower in ethanol treated group, In the normal group. The activity of serum alanine aminotransferase and aspartate aminotransferase is well known to be increased by hepatic tissue injury and is widely used as an index of hepatic tissue damage in clinical practice (Reitman S. and Frankel S., A colorimetric method for the determination of serum glutamic oxaloacetic pyruvic transaminase. Am. J. Clin. Pathol. 28: 58-63, 1957.).
에탄올 대조군에서 혈청 알라닌 아미노전이효소 및 아스파르테이트 아미노 전이효소의 활성이 현저히 증가된 것은 급성 에탄올의 독성에 의해 나타난 것으로 생각되며, 각 시료 추출물 첨가식이에 의해 급성 에탄올의 독성이 예방 혹은 경감된 것으로 관찰되었다.The significant increase in the activity of serum alanine aminotransferase and aspartate aminotransferase in the ethanol control group was thought to be caused by the toxicity of acute ethanol and the toxicity of acute ethanol was prevented or reduced by the addition of each sample extract Respectively.
3) 간 조직 글루타치온 함량 및 과산화지질 및 중성지질 함량3) liver tissue glutathione content, lipid peroxide and neutral lipid content
4주간 실험식이로 성장시키는 동안 만성적 에탄올 투여에 의해 발기부전을 유도한 흰쥐의 간 조직 글루타치온의 함량과 과산화지질의 함량, 그리고 간 조직 중성지방 함량을 관찰한 결과는 도 3에 제시하였다. The results of observing the contents of glutathione, lipid peroxidation and hepatic triglyceride in rats induced by erythropoietin induced by chronic ethanol administration during the 4 weeks experimental diet were shown in Fig.
글루타치온는 우리 몸에서 과산화지질을 무독화 시키는 작용을 한다고 알려져 있다(Ohkawa H., Ohishi N. and Yagi K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95: 248-25, 1979.). It is known that glutathione acts to detoxify peroxidized lipids in our body (Ohkawa H., Ohishi N. and Yagi K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction, Anal. Biochem., 95: 248-25 , 1979).
만성적 에탄올 투여를 한 홍삼(BR), 홍삼 혼합 조성물(BRM), 홍삼 발효 혼합 조성물(BRFM) 식이군의 경우 실험대조군(EN)에 비해 글루타치온 함량이 증가하는 것으로 관찰되었다. 반면 과산화지질 함량은 EN군에서 월등히 증가한 반면 홍삼, 홍삼 혼합 조성물 및 홍삼 발효 혼합 조성물 식이군에서는 월등히 감소하여 대조군(NC)과 비슷한 수준의 함량을 나타내었다.Glutathione contents were increased in rats fed with chronic ethanol (BR), red ginseng mixed composition (BRM), and red ginseng fermented mixed composition (BRFM) diets compared to the experimental control (EN). On the other hand, the lipid peroxidation contents were significantly increased in the EN group, whereas the content of lipid peroxidation was significantly decreased in the group of red ginseng, red ginseng mixed composition and red ginseng fermented mixed composition, and the content was similar to that of the control group (NC).
과산화지질은 세포막을 구성하는 다가불포화지방산이 활성산소종(reactive oxygen species, ROS)에 의해 생성되는 것으로 세포막 손상의 지표로 알려져 있다(Vladislav E., Dana K., Monika B., The effect of curcumin on cadmium-induced oxidative damage and trace elements level in the liver of rats and mice. Toxicol Lett 151: 79-85, 2004.). 또한, 과산화지질은 글루타치온를 이용하는 글루타치온 퍼옥시다아제 및 글루타치온 에스 트렌스라제에 의해 대응하는 에탄올성지방(lipid alcohol)로 환원되어 무독화시키는데 글루타치온가 관여(Hausburg M. A., Dekrey G. K., Salmen J. J., Palic M. R. and Gardiner C. S., Effects of paraquat on development of preimplantation embryos in vivo and in vitro. Reprod. Toxicol. 20: 239-246, 2005.) 하는 것으로 보고되고 있다. 또한, 조직 손상 시 일정시간 경과 후에는 조직 손상을 방어 혹은 경감시키기 위하여 글루타치온 함량이 신속하게 증가하는 것으로 알려져 있으며(Wang R. S., Nakajima T. and Honma T., Different change patterns of the isozymes of cytochrome p450 and glutathione S-transferases in chemically induced liver damage in rat. Ind. Health. 37: 440-448, 2000.), 급·만성 에탄올 섭취에 의해 간 조직 과산화지질의 함량이 증가한다고 보고되고 있다(Lieber C. S., Hepatic, metabolic and toxic effects of ethanol. Alcohol Clin. Exp. Res. 15: 573-592, 1991.). Lipid peroxidation is known to be an indicator of cell membrane damage as polyunsaturated fatty acids constituting the cell membrane are produced by reactive oxygen species (ROS) (Vladislav E., Dana K., Monika B., The effect of curcumin on cadmium-induced oxidative damage and trace elements levels in the liver of rats and mice. Toxicol Lett 151: 79-85, 2004.). In addition, lipid peroxidase is reduced to the corresponding ethanolic lipid alcohol by glutathione peroxidase and glutathione peroxidase using glutathione, and glutathione is involved in detoxification (Hausburg MA, Dekrey GK, Salman JJ, Palic MR and Gardiner CS, Toxicol. 20: 239-246, 2005.) have been reported to be involved in the development of preimplantation embryos in vivo and in vitro. In addition, it is known that the glutathione content is rapidly increased to prevent or reduce tissue damage after a certain period of time in tissue damage (Wang RS, Nakajima T. and Honma T., Different change patterns of the isozymes of cytochrome p450 and (Lieber CS, Hepatic), and hepatic lipid peroxidation (LH) in the liver, liver, and kidney , metabolic and toxic effects of ethanol. Alcohol Clin. Exp. Res. 15: 573-592, 1991.).
이러한 보고들을 종합해 볼 때, 에탄올의 급성독성에 의해 에탄올대조군(EN)에서 간 조직 과산화지질의 함량이 증가되었으며 이로 인한 간 조직 손상을 경감시키기 위한 생체의 적응현상으로 글루타치온 함량이 증기된 것으로 사료되며, 정도의 차이는 있으나 홍삼(BR), 홍삼 혼합 조성물(BRM) 및 홍삼 발효 혼합 조성물(BRFM)의 경우 이들에 함유되어 있는 다양한 유용성분들은 에탄올 급성 독성을 예방 혹은 완화시키는 작용이 있어 간 조직 과산화지질의 함량이 낮게 나타난 것으로 판단된다. These results suggest that the acute toxicity of ethanol increased the content of hepatic lipid peroxidation in the ethanol control (EN) and the glutathione content was increased due to adaptation of the biomass to alleviate the hepatic tissue damage caused by the ethanol However, in the case of red ginseng (BR), red ginseng mixed composition (BRM) and red ginseng fermented mixed composition (BRFM), various kinds of oil soluble ingredients thereof have an action to prevent or alleviate the acute toxicity of ethanol, And the content of lipid peroxide is low.
특히, 홍삼 발효 혼합 조성물(BRFM) 식이군은 글루타치온은 정상적인 수치를 유지하면서 과산화지질과 중성지방의 함량을 현저하게 감소되는 것을 보아 균주고체발효와 숙성에 의하여 생성되는 다양한 유용물질이 에탄올성 간 독성의 예방 및 회복에 도움을 주는 것으로 판단된다.Particularly, in the group of fermented red ginseng fermented product (BRFM), the contents of lipid peroxidation and triglyceride were remarkably decreased while glutathione was kept at a normal level. The various useful substances produced by the fermentation and aging of the strain were ethanol- And to prevent and recover from the disease.
간 조직의 중성지방함량에서는 에탄올만 만성적으로 경구 투여한 에탄올 대조군에서는 정상군에 비해 간 조직 중성지방의 함량이 현저히 증가하였으나 홍삼(BR), 홍삼 혼합 조성물(BRM), 홍삼 발효 혼합 조성물(BRFM) 식이군의 경우 월등히 감소되는 결과를 나타내었다. 에탄올의 급·만성 섭취는 간 조직의 중성지방 합성은 증가되지만, 초저밀도 지단백질(VLDL)의 아포지단백질(apolipoprotein)의 결핍으로 인하여 간 조직에 중성지질 배출되지 못하고 축적되어 지방간을 야기하는 것으로 알려져 있다(Lieber C. S., Hepatic, metabolic and toxic effects of ethanol. Alcohol Clin. Exp. Res. 15: 573-592, 1991.). 그러므로 에탄올대조군에서 간 조직 중성지방의 함량이 증가된 것은 에탄올의 급성 독성에 의해 나타난 것으로 사료되며 이상의 실험 결과들을 종합해 볼 때 홍삼을 함유하는 발효 혼합 조성물의 경우 에탄올에 의한 독성을 예방 혹은 경감시켜 발기부전에 영향을 미치는 신진대사 작용을 원활하게 함에 따라 발기부전증상의 개선에도 도움을 줄 수 있을 것으로 사료된다. The content of triglyceride in hepatic tissues was significantly higher than that of ethanol in chronically orally administered ethanol control group, but the content of hepatic triglyceride was significantly higher than that of normal group. However, red ginseng (BR), red ginseng mixed composition (BRM) Dietary group was significantly decreased. The acute and chronic intake of ethanol is known to increase the triglyceride synthesis of liver tissues, but it is known that the deficiency of apolipoprotein of hypolipidemic lipoprotein (VLDL) causes accumulation of neutral lipids in liver tissues and accumulation of fatty liver (Lieber CS, Hepatic, metabolic and toxic effects of ethanol. Alcohol Clin. Exp. Res. 15: 573-592, 1991.). Therefore, it is considered that the increase of hepatic triglyceride content in the ethanol control group is caused by the acute toxicity of ethanol. Based on the above results, in case of the fermented mixed composition containing red ginseng, the toxicity by ethanol is prevented or reduced It may be helpful to improve the erectile dysfunction symptoms by facilitating the metabolism that affects erectile dysfunction.
4) 음경 해면체 조직의 활성산소 소거계 효소류의 활성4) Activity of enzymes in the erythrocyte scavenging system of corpus cavernosum
기질적 원인에 의한 발기부전은 크게 내분비적인 원인과 신경성 원인, 혈관성 원인, 전신질환 및 기타 원인으로 구분된다. 특히, 에탄올은 발기 능력을 감소시키며, 간 손상이 없는 경우라도 알코올 중독자 남성에게서 비가역적인 전립선 위축과 함께 세정관의 위축과 정자 세포의 상실을 야기한다. Erectile dysfunction caused by organic causes is divided into endocrine, neurogenic, vascular, systemic and other causes. In particular, ethanol reduces erectile function and causes irreversible prostate atrophy and loss of spermatocytes and sperm cells in alcoholic men, even in the absence of liver damage.
발기부전은 음경 해면체조직 중에 정상적으로 혈액이 유입이 이루어지지 못하는 현상으로서 혈액의 정상적인 유입과 충혈이 이루어지면 발기부전을 개선할 수 있다. 음경해면체 조직중의 혈관 이완 반응은 혈관 내피세포에 존재하는 일종의 호르몬성 물질인 혈관내피 이완인자 즉 일산화질소(nitric oxide, NO)에 의해서 이루어 진다고 알려져 있다. 일산화 질소는 체내에서 니트릭옥시드신타아제(nitric oxide synthase, NOS)의 생화학적 작용에 의하여 생합성 되어 진다.Erectile dysfunction is a phenomenon in which blood can not flow normally into the corpus cavernosum tissue, and normal inflow of blood and congestion can improve erectile dysfunction. It is known that the vascular relaxation response in the corpus cavernosum is caused by vascular endothelial relaxation factor, nitric oxide (NO), which is a type of hormone present in vascular endothelial cells. Nitric oxide is biosynthesized by the biochemical action of nitric oxide synthase (NOS) in the body.
니트릭옥시드신타아제의 활성과 스트레스에 의한 활성산소 소거계 효소류의 활성을 평가하여 발기부전의 개선효과를 측정하고자 4주간 실험식이로 성장시키는 동안 만성적 에탄올 투여에 의해 발기부전을 유도한 흰쥐 음경 해면체 조직의 니트릭옥시드 신타아제, 슈퍼옥시드 디스무타아제, 글루타치온 퍼옥시다아제, 카탈라아제 및 글루타치온-에스트렌스퍼라제 활성변동은 표 9에 제시하였다. To evaluate the effect of active oxygen scavenging enzymes on the activity and stress of nitric oxide synthase, we measured the effects of erectile dysfunction induced by chronic ethanol administration during 4 weeks of experimental diet. The changes in nitric oxide synthase, superoxide dismutase, glutathione peroxidase, catalase and glutathione-esterspreferase activity of the corpus cavernosum tissue are shown in Table 9.
홍삼(BR), 홍삼혼합조성물(BRM), 홍삼발효혼합조성물(BRFM) 식이군에서 니트릭옥시드 신타아제, 슈퍼옥시드 디스무타아제, 글루타치온 퍼옥시다아제, 카탈라아제의 활성, 글루타치온 에스 트렌스퍼라제 활성은 에탄올대조군에 비해 유의하게 증가하였으며 특히 홍삼발효혼합조성물 식이군에서 현저히 증가하였다. The activity of nitrite oxide synthase, superoxide dismutase, glutathione peroxidase, catalase, glutathione estransferase activity in BR, red ginseng mixture (BRM) and red ginseng fermented mixed composition (BRFM) Was significantly increased compared to the ethanol control group, especially in the red ginseng fermented mixed composition diet group.
슈퍼옥시드 디스무타아제는 초과산화물(O2 -)을 독성이 한 단계 낮은 과산화수소(H2O2)로 전환시키고 최종적으로 카탈라아제 및 글루타치온 퍼옥시다아제는 과산화수소를 물로 전환하여 무독화 시킨다. 또한, 글루타치온 에스 트렌스퍼라제는 미쳐 제거하지 못한 활성산소종이 과산화지질을 만들었을 경우 글루타치온을 이용하여 이를 독성이 낮은 에탄올성지방로 전환하여 무독화 시킨다(Im M. J., Manson P. N., Bulkley G. B., Hoopes J. E., Effects of superoxide dismutase and allopurinol in survival of acute island skin flaps. Ann. Surgery 201: 357-359, 1985.; Jacoby J. B., The glutathione S-transferase: a group of multifunctional detoxification proteins. Adv. Enzymol. Relat. Areas. Mol. Biol. 46: 383-414, 1978.). Superoxide dismutase converts excess oxygen (O 2 - ) to toxic one-step hydrogen peroxide (H 2 O 2 ), and catalase and glutathione peroxidase ultimately detoxify hydrogen peroxide into water. In addition, glutathione estransferase can be used as an active oxygen species when it is not removed, and when it is made into lipid peroxides, it is converted to an ethanolic fat with low toxicity using glutathione (Im MJ, Manson PN, Bulkley GB, Hoopes JE , Effects of superoxide dismutase and allopurinol on survival of acute island skin flaps. Ann. Surgery 201: 357-359, 1985 .; Jacoby JB, The glutathione S-transferase: a group of multifunctional detoxification proteins. Mol Biol 46: 383-414, 1978.).
이상의 결과 홍삼발효혼합조성물 추출물은 고환의 항산화계 효소류의 활성증가에 도움을 주며, 급성, 만성적 에탄올의 투여에도 니트릭옥시드신타아제의 활성증진에 따라 에탄올에 의한 조직 손상을 예방 및 발기부전 증상을 완화할 수 있는 것으로 관찰되었다. As a result, the extract of fermented red ginseng composition was found to be effective in increasing the activity of antioxidant enzymes of the testes. In addition, acute and chronic ethanol administration also promoted the activity of nitric oxide synthase to prevent tissue damage caused by ethanol, It was observed that the symptoms could be alleviated.
표 9에서 니트릭옥시드-신타아제 단위는 Δ흡광도/단백질㎎, 슈퍼옥시드 디스무타아제의 단위는 유닛(헤마토자일렌의 자동산화를 50% 억제하는 단백의 함량)이며, 글루타치온 퍼옥시다아제의 단위는 nmole/단백질㎎, 카탈라아제의 단위: nmole/단백질㎎, 글루타치온 에스 트렌스퍼라제의 단위는 nmole/단백질㎎이다. 또한, 데이터는 실험동물 7마리의 “평균값 ± 표준편차”로 나타내었다.In Table 9, the unit of nitric oxide-synthase unit is? Absorption / protein mg, the unit of superoxide dismutase is unit (the content of protein that inhibits 50% of autoxidation of hematoxylin), and glutathione peroxidase Unit of nmole / protein mg, the unit of catalase: nmole / protein mg, and the unit of glutathione estransferase is nmole / protein mg. The data were also expressed as "mean value ± standard deviation" of 7 animals.
이상의 실험 결과로부터 다음과 같은 사실을 확인할 수 있었다.From the above experimental results, the following facts were confirmed.
먼저, 2-bromopropane(고환손상 유도제)을 처리한 흰쥐의 고환과 타 장기에 대한 영향 및 산화적 손상 정도에 미치는 영향에 대한 실험결과로부터 간 조직 및 고환 조직에 미치는 영향을 비교한 결과, 홍삼 혼합 조성물 및 홍삼 발효 혼합 조성물 식이는 홍삼 단독 식이에 비하여 2-브로모프로판 노출군의 고환 크기를 다소 회복시켰으며, 2-브로모프로판에 의해 손상된 장기조직 중 특히 간 세포의 회복에 특이성을 가지며, 손상된 고환기능의 복구에도 잠재적 효능이 있는 것으로 관찰되었다. 또한, 홍삼 발효 혼합 식이군이 간 조직 및 고환조직에서의 항산화계 효소류의 활성을 증가시켜며, 조직의 산화적 손상을 경감시키는 것으로 나타났다. First, the effects of 2-bromopropane (testis damage inducer) on the testis and other organs of rats and the effects of oxidative damage on the liver and testicular tissues were compared. Compared with red ginseng alone, the composition and composition of the fermented red ginseng composition slightly restored the testis size of the 2-bromopropane-exposed group, and were specific for the recovery of liver cells, especially of organ tissues damaged by 2-bromopropane, Potential efficacy has also been observed for repair of damaged testicular function. In addition, the red ginseng fermented mixed diet group increased the activity of antioxidant enzymes in liver and testicular tissues, and it alleviated the oxidative damage of tissues.
다음으로, 홍삼발효혼합조성물이 에탄올에 의한 발기부전을 유도한 흰쥐의 간 해독 작용, 활성산소(Reactive Oxygen Species, ROS) 소거계 효소활성 및 성기능 개선에 미치는 영향에 대한 실험결과로부터 간 조직 및 음경 해면체 조직에 미치는 영향을 비교한 결과, 해독에 관여하는 글루타치온의 함량은 증가하였고, 과산화물 함량도 정상군 수준으로 회복되었으며, 중성지방의 함량을 현저히 낮추는 효과를 확인하였다. 간 조직 손상 정도를 나타내는 혈청 알라닌 아미노전이효소의 활성은 모든 실험군에서 정상군 수준으로 회복되었다. 활성산소종의 작용을 억제하는 항산화계 효소의 활성은 홍삼발효혼합조성물 추출물에서 높게 나타났으며, 홍삼발효혼합조성물 추출물은 고환의 항산화계 효소류의 활성증가에 도움을 주며, 급성, 만성적 에탄올의 투여에도 니트릭옥시드신타아제의 활성증진에 따라 에탄올에 의한 조직 손상을 예방 및 발기부전 증상을 완화할 수 있는 것으로 관찰되었다. Next, the effects of the red ginseng fermentation mixture composition on liver detoxification, reactive oxygen species (ROS) cleavage enzyme activity and sexual function improvement in rats induced by erectile dysfunction caused by ethanol were examined from liver tissue and penis As a result of comparing the effects on the corpus cavernosum, the content of glutathione involved in detoxification was increased, the peroxide content was restored to the normal group level, and the effect of significantly lowering the triglyceride content was confirmed. Serum alanine aminotransferase activity, which indicates the degree of liver damage, recovered to normal levels in all experimental groups. The activity of antioxidant enzymes that inhibit the action of reactive oxygen species was high in the extract of mixed composition of fermented red ginseng. The extract of fermented red ginseng composition was found to be effective in increasing the activity of antioxidant enzymes of the testes and the activity of acute and chronic ethanol It was also observed that administration of nitric oxide synthase improves the activity of ethanol to prevent tissue damage and alleviate erectile dysfunction.
본 발명의 권리는 위에서 설명된 실시예에 한정되지 않고 청구범위에 기재된 바에 의해 정의되며, 본 발명의 분야에서 통상의 지식을 가진 자가 청구범위에 기재된 권리범위 내에서 다양한 변형과 개작을 할 수 있다는 것은 자명하다.It is to be understood that the invention is not limited to the disclosed embodiment, but is capable of many modifications and variations within the scope of the appended claims. It is self-evident.
Claims (5)
상기 전처리된 원료를 발효 미생물과 혼합하여 숙성하여 발효 혼합 분말을 제조하는 단계;
상기 발효 혼합 분말 및 홍삼 분말을 혼합하여 홍삼 발효 혼합 분말을 제조하는 단계;
상기 홍삼 발효 혼합 분말 중 일부를 추출 및 농축하여 혼합 발효 추출 농축액을 제조하는 단계;
상기 홍삼 발효 혼합 분말에 상기 혼합 발효 추출 농축액을 분사한 후 건조하여 홍삼 혼합 조성물을 제조하는 단계;
를 포함하는 것을 특징으로 하는 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물의 제조방법.
A pretreatment step of pretreating a raw material of a fermented mixed powder composed of maca, damiana, pumpkin seed, soybean, ginger, cordyceps, corn oil, gougia, silkworm, and bamboo;
Mixing the pretreated raw material with a fermenting microorganism and aging the mixture to prepare a fermentation mixed powder;
Mixing the fermentation mixed powder and the red ginseng powder to prepare a red ginseng fermentation mixed powder;
Extracting and concentrating a part of the red ginseng fermentation mixed powder to prepare a concentrated fermentation extract concentrate;
Mixing the red ginseng fermentation mixed powder with the mixed fermentation extraction concentrate and drying the mixture to prepare a red ginseng mixed composition;
Wherein the fermented red ginseng composition comprises a fermented red ginseng mixture.
상기 전처리 단계는 상기 원료를 각각 가압살균, 로스팅, 급속 동결 건조한 후 이를 분쇄하는 단계로 이루어지는 것을 특징으로 하는 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물의 제조방법.
The method of claim 3,
Wherein the pretreatment step comprises autoclaving, roasting, rapid freeze-drying, and pulverizing the raw materials, respectively.
상기 홍삼 발효 혼합 조성물을 제조하는 단계는 상기 홍삼 발효 혼합 분말에 대하여 상기 혼합 발효 추출 농축액 10 중량부를 분사한 후, 함수율이 5% 이하가 되도록 건조하는 것을 특징으로 하는 홍삼 발효 혼합 조성물을 포함하는 기능성 식품 조성물의 제조방법.The method of claim 3,
The fermenting mixed composition of red ginseng is prepared by spraying 10 parts by weight of the concentrated fermentation broth with the red ginseng fermentation mixed powder and drying the mixture so that the moisture content is 5% or less. ≪ / RTI >
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160099334A KR101688542B1 (en) | 2016-08-04 | 2016-08-04 | Functional Food Composition Comprising Red Ginseng Mixed Composition and Manufacturing Method Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160099334A KR101688542B1 (en) | 2016-08-04 | 2016-08-04 | Functional Food Composition Comprising Red Ginseng Mixed Composition and Manufacturing Method Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101688542B1 true KR101688542B1 (en) | 2016-12-21 |
Family
ID=57734630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160099334A KR101688542B1 (en) | 2016-08-04 | 2016-08-04 | Functional Food Composition Comprising Red Ginseng Mixed Composition and Manufacturing Method Thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101688542B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102551019B1 (en) * | 2023-02-14 | 2023-07-04 | 조민준 | Method for producing extract of fermented pumpkin seed cultured in mushroom mycelium |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100538717B1 (en) | 2001-10-31 | 2005-12-26 | 주식회사 케이티앤지 | Compositin of Korean Red Ginseng Including Oriental Herbs for Improving Sexual Function and Manufacturing Method the Same and Its Use |
KR100850503B1 (en) | 2006-12-19 | 2008-08-05 | 경희대학교 산학협력단 | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex |
KR101204875B1 (en) | 2011-11-18 | 2012-11-27 | 김병돈 | A functional sauce containing Fermentation Products of Cudrania tricuspidata and Manufacturing method thereo |
KR20140016116A (en) * | 2012-07-30 | 2014-02-07 | 구자성 | Method for fermented kyeong-ok-go by using microorganisms |
KR101385657B1 (en) | 2011-08-12 | 2014-04-21 | 주식회사한국전통의학연구소 | Pharmaceutical Composition Comprising Herbal Extracts for Preventing or Treating Importence, and Functional Food Comprising This Extracts |
KR101454315B1 (en) * | 2013-05-13 | 2014-10-27 | 개성인삼열매영농조합법인 | Manufacturing method of softness fermented Black Ginseng |
KR101596728B1 (en) * | 2015-08-11 | 2016-03-07 | 김현성 | Composition comprising zinc/red ginseng, octacosanol and vitamin for preventing and ameliorating andropause symptoms |
-
2016
- 2016-08-04 KR KR1020160099334A patent/KR101688542B1/en active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100538717B1 (en) | 2001-10-31 | 2005-12-26 | 주식회사 케이티앤지 | Compositin of Korean Red Ginseng Including Oriental Herbs for Improving Sexual Function and Manufacturing Method the Same and Its Use |
KR100850503B1 (en) | 2006-12-19 | 2008-08-05 | 경희대학교 산학협력단 | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex |
KR101385657B1 (en) | 2011-08-12 | 2014-04-21 | 주식회사한국전통의학연구소 | Pharmaceutical Composition Comprising Herbal Extracts for Preventing or Treating Importence, and Functional Food Comprising This Extracts |
KR101204875B1 (en) | 2011-11-18 | 2012-11-27 | 김병돈 | A functional sauce containing Fermentation Products of Cudrania tricuspidata and Manufacturing method thereo |
KR20140016116A (en) * | 2012-07-30 | 2014-02-07 | 구자성 | Method for fermented kyeong-ok-go by using microorganisms |
KR101454315B1 (en) * | 2013-05-13 | 2014-10-27 | 개성인삼열매영농조합법인 | Manufacturing method of softness fermented Black Ginseng |
KR101596728B1 (en) * | 2015-08-11 | 2016-03-07 | 김현성 | Composition comprising zinc/red ginseng, octacosanol and vitamin for preventing and ameliorating andropause symptoms |
Non-Patent Citations (8)
Title |
---|
Adimoelja A., Int. J. Androl. 23: 82-84, 2000. |
Gonzales G. F., Cordova A., Gonzales C., Chung A., Vega K., Villena A., Asian J. Androl. 3: 301-303, 2003. |
Gonzales G. F., Cordova A., Vega K., Chung A., Villena A., Gonez C., Castillo S., 34: 367-372, 2002. |
Hong B., Ji Y. H., Hong J. H., Nam K. Y., Ahn T. Y., J. Urol. 168: 2070-2073, 2002. |
MacKay D., Altern. Med. Rev. 9: 4-16, 2004. |
Murphy L. L., Lee T. J., Annals NY Acad Sci. 962: 372-377, 2002. |
남성건강식품 자생단 생생후기!. 네이버블로그, [online], 2016.07.31., 인터넷 <URL: http://blog.naver.com/keaps/220775816626>* * |
남성건강식품 자생단 생생후기!. 네이버블로그, [online], 2016.07.31., 인터넷 <URL: http://blog.naver.com/keaps/220775816626>* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102551019B1 (en) * | 2023-02-14 | 2023-07-04 | 조민준 | Method for producing extract of fermented pumpkin seed cultured in mushroom mycelium |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5568806B2 (en) | Diabetes or diabetes complication preventive | |
JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
Ayodeji et al. | Tetracarpidium conophorum (African walnut) Hutch. & Dalziel: Ethnomedicinal uses and its therapeutic activities | |
Edo et al. | Cyperus esculentus (tiger nut): its application in agriculture, food, health and nutrition. A review | |
KR20150040392A (en) | undiluted stevia liquid and the berages, and its manufacturing method | |
CN103462020A (en) | Natural nutrient capable of inhibiting harm of heavy metal and pesticide residue | |
KR20040063690A (en) | Functional liquor | |
ALIKWE et al. | Evaluation of the chemical and phytochemical constituents of Alchornea cordifolia leaf meal as potential feed for monogastric livestock | |
KR20040063680A (en) | Functional vinegar containing diet enzyme, herb medicines and functional materials | |
KR101688542B1 (en) | Functional Food Composition Comprising Red Ginseng Mixed Composition and Manufacturing Method Thereof | |
Shahrajabian et al. | Carob (Ceratonia siliqua L.), Pharmacological and Phytochemical Activities of Neglected Legume of the Mediterranean Basin, as Functional Food | |
CN111165694B (en) | Composite black jerusalem artichoke functional nutrient solution and preparation method thereof | |
KR20190113721A (en) | Onion Coat composition Using An Enzyme With Stevia Extract And Method thereof | |
Lim et al. | Mucuna pruriens | |
CN111374309A (en) | Composition capable of regulating human immune system and preparation method thereof | |
KR101811227B1 (en) | Composition for Immune Enhancement, Fatigue Recovery, Physiologically Active, Detoxification Comprising Extracts of Lycium chinence miller, Rubus coreanus Miq. & Schisandra chinensis | |
KR102683022B1 (en) | METHOD FOR MANUFACTURING SEASONING SAUCE FOR PORK USING Flammulina velutipes EXTRACT AND SEASONING SAUCE FOR PORK PRODUCED THEREBY | |
CN109620858A (en) | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes | |
KR102515041B1 (en) | Health food using sprout ginseng and manufacturing method of the same | |
KR101547576B1 (en) | Method of preparing functional functional grain | |
KR102048723B1 (en) | Method for manufacturing functional juice | |
Siddiqui et al. | Almond (Prunus amygdalus L.): A source of revitalizing health and its therapeutic application | |
KR20170021092A (en) | Manufacturing Method of Health Functional Beverage Comprising Roasting Mung Beans, Soy and Loquat Leaf and Thereof Beverage | |
Özcan | Date (Phoenix dactylifera L.) fruit and seeds: composition, using and bioactive properties-a review. | |
KR20040064539A (en) | Functional boiled fish paste containing diet enzyme, herb medicines and functional materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20190930 Year of fee payment: 4 |